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Abstract 
AMP-activated protein kinase (AMPK) is an enzyme that senses and regulates 
cellular energy balance thus playing a key role in homeostasis. As such it is a target 
for treatment of metabolic disorders such as type II diabetes. AMPK is a 
hetero-trimeric complex composed of an α, β and γ subunit. α contains the catalytic 
kinase domain, β is a scaffolding subunit that enables complex formation and γ 
monitors cellular energy via nucleotide binding to its CBS domains. AMPK is 
primarily activated by phosphorylation at Thr-172 on the activation loop in the 
kinase domain. It exerts its cellular effects via phosphorylation of a range of 
downstream targets involved in different aspects of energy production & utilization. 
 
The aim of this thesis is to characterize the mechanistic basis of energy regulation of 
mammalian AMPK via structural and binding measurements. Fluorescence studies 
have been facilitated by the use of N-methylanthraniloyl (mant) labelled AMP and of 
β-Nicotinamide adenine dinucleotide 2’-phosphate (NADPH) to monitor 
competition with AMP, ADP and ATP. A number of mutations in the γ subunit, 
which interfere with the normal function of AMPK and cause Wolff-Parkinson-
White (WPW) syndrome, have also assessed for changes in nucleotide binding 
affinities and potential implications for the regulation of kinase activity. 
 
Thermal denaturation experiments are used to investigate the stabilizing effects of 
nucleotides and other small molecule ligands. This method was used in a low 
throughput screen against an enriched list of compounds selected from an in silico 
screen to try to identify novel activators.  
 
I have also determined the structure of the regulatory fragment of the enzyme bound 
to 5-aminoimidazole-4-carboximide riboside monophosphate (ZMP), an 
intermediate on the biosynthetic route to AMP, the fluorescence reporter mant-AMP 
and the WPW mutants Arg298ÆGly, Arg69ÆGln and His150ÆArg. The structures 
of the mutants have revealed that nucleotide binding is impaired due to a reduced 
affinity for the nucleotides thus affecting the regulation of the kinase.   5
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1. Introduction 
Living organisms need energy in order to carry out vital cellular processes such as 
synthesis of macromolecules, cell division and movement. In mammalians, energy is 
derived from foods such as carbohydrates, fatty acids and proteins. These nutrients 
are absorbed from the gut and dispersed through the blood stream from where they 
are taken up by cells throughout the body. A key molecule used as a source of 
energy in cells is glucose. Excess glucose is stored by conversion into glycogen. 
When energy is needed, glucose, through a series of cellular processes such as 
glycolysis, the Krebs cycle and oxidative phosphorylation, is used to regenerate 
5’-Adenosine triphosphate (ATP). ATP is an immediately available nucleotide that 
liberates large amounts of energy when it is hydrolyzed to 5’-Adenosine diphosphate 
(ADP) and phosphate 
1.  
 
In a typical cell, there is a continuous turnover of ATP and it is clearly vital to have 
an efficient mechanism for monitoring ATP consumption and regulating its 
regeneration so that cellular homeostasis is not compromised. 
 
1.1  AMP-activated protein kinase (AMPK) 
AMPK is an ubiquitously expressed protein kinase that senses and regulates cellular 
energy balance, playing a central role in regulating cellular metabolism 
2. AMPK 
activity in cells is relatively low in situations where glucose and oxygen levels are 
optimal and the cell is not under metabolic stress (e.g. myocytes at rest). Under these 
conditions, ATP, ADP & AMP concentration are around 2-5 mM, 200-500 μM and 
2-5 μM, respectively 
3. AMPK is thought to be activated by a number of stimuli that 
act to increase the AMP:ATP ratio  
4-5. Once AMPK is activated, it works on a wide 
range of target enzymes to restore energy levels by inhibiting energy-requiring 
pathways such as protein or fatty acid synthesis and at the same time, it enhances 
ATP-producing pathways such as glycolysis and fatty acid oxidation. 
 
   16
1.1.1 Structure of AMPK 
AMPK is a hetero-trimeric complex composed of one copy each of α, β and γ 
subunits (Fig 1.1). Homologues of all three subunits have been identified in yeasts, 
which form the SNF1 (Sucrose Non-Fermenting-1) complex in S. Cerevisiae and 
SNF-like protein in S. Pombe (see section 1.1.3.2) 
6-7. In mammals, two isoforms 
each for α and β are known (α1, α2, β1 and β2) and three different isoforms of γ (γ1, 
γ2 and γ3) together with alternate splicing forms 
8. Different combinations of 
isoforms allow the formation of distinct hetero-trimeric complexes which have been 
suggested to be tissue-specific 
8-11. α is the catalytic subunit which has a 
conventional kinase domain at its amino terminus including a regulatory 
phosphorylation site at Thr-172 (Fig 1.1). The crystal structure of the kinase domain 
of AMPK has been published 
12, but the activation loop is largely disordered, 
presumably because it is not phosphorylated. The α subunit also interacts with the 
β-subunit through its C-terminus. The β-subunit acts as a scaffold to which the other 
two subunits bind; it also contains a so-called glycogen-binding domain (GBD) 
towards its amino terminus, which has been proposed to play a role in sensing 
glycogen availability 
11,13 (see section 1.1.2.3). A crystal structure of the isolated 
GBD from mammalian AMPK has been published revealing the carbohydrate 
binding pocket responsible for binding to glycogen 
14-15. The γ subunit of AMPK is 
responsible for the energy sensing properties of the complex because it binds 
competitively to either AMP, ADP or ATP via its two Bateman domains 
16. A 
Bateman domain is made up from a pair of CBS motifs 
17, termed after cystathionine 
β-synthase, the human protein where this domain was initially found. A CBS motif 
is a conserved domain of about 60 amino acids which are present in over a thousand 
other known proteins. The crystal structures of several proteins containing CBS 
domains have been solved 
18-20. Although the function of CBS motifs in most of 
these proteins remains to be established, they often occur in the context of metabolic 
enzymes, transcriptional regulators, ion channels and transporters 
21. In some 
proteins CBS motifs are responsible for binding to adenosine-containing ligands 
such as AMP, ATP or S-adenosyl methionine 
22. In AMPK, the four CBS motifs that   17
make up the γ subunit have been found to be responsible for monitoring cellular 
energy by binding competitively to either AMP or ATP 
16.  
 
 
Figure 1.1: Diagrammatic representation of the hetero-trimeric complex of AMPK: 
the α subunit is indicated in cyan, β in green and γ in red. 
 
 
1.1.2 Regulation  of  AMPK 
The enzyme activity of AMPK is highly dependant on the phosphorylation status of 
the activation loop of the kinase domain. Activity increases 100-fold upon 
phosphorylation by upstream kinases 
4. AMPK is activated by various stimuli such 
as hypoxia 
23, oxidative stress 
24, glucose deprivation 
25, ischemia 
26-27 and physical 
exercise 
28-29. The outcome of all of these effects is to increase the cellular 
AMP/ATP ratio. AMPK has also been found to be regulated by glycogen and 
hormones 
30.  
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1.1.2.1 Reversible phosphorylation 
The activity of many proteins is modulated by post translational modification. 
Acetylation, glycosylation and phosphorylation are all common covalent 
modifications. Protein phosphorylation refers to the reversible attachment of a 
phosphate group to hydroxyl side chains of serine, threonine and tyrosine, and is 
some cases to the side chain of histidine residues 
31-32. The phosphorylation cycle is 
catalyzed by a protein kinase and a protein phosphatase (PP).  
 
Figure 1.2: Regulation of phosphorylation: phosphorylation and dephosphorylation 
are highly favourable reactions driven ultimately by the hydrolysis of ATP. 
 
 
In animal cells reversible phosphorylation is the major intracellular mechanism by 
which cells respond to first messengers, which include growth factors, nutrients and 
hormones etc. 
33. These extracellular stimuli can then give rise to the sequential 
phosphorylation of protein kinases inside the cell in a protein kinase cascade which 
amplifies the original signal. Second messengers can be formed in micromolar 
concentrations in response to nanomolar levels of external signal molecules 
34. To 
date, about 518 protein kinases have been identified in the human genome which are 
involved in a myriad of cellular processes; their misregulation often results in 
disease 
35. The development of specific activators and inhibitors for protein kinases 
is increasing and kinases are now the second most important group of drug targets, 
after G-protein-coupled receptors 
35. As a consequence a lot of effort has been 
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- + ADP 
O
-
O 
protein  
kinase 
protein  
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ATP  ADP 
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invested in determining their 3-dimensional structures and currently there are about 
50 unique protein kinase crystal structures 
36. 
 
 
AMPK belongs to a well characterized protein kinase cascade. Two of the upstream 
kinases (AMPKKs) that catalyze the phosphorylation of AMPK at Thr-172 are 
LKB1 and Ca
2+/Calmodulin-dependent protein Kinase Kinases (CaMKKs) 
37-40 
(Fig.1.3). LKB1 is the major upstream kinase and is a tumor suppressor which is 
mutated in Peutz-Jeghers cancer predisposition syndrome. Peutz-Jeghers syndrome 
patients are characterized by the development of numerous benign intestinal polyps 
(hamartomas). The LKB1 gene generates two alternative splicing patterns whose 
protein products have different C-terminal sequences: a long 50 kDa form, LKB1L, 
and a short 48-kDa form, LKB1S 
41. LKB1L is widely expressed in mammalian 
tissues, whereas LKB1S is primarily expressed in the testis. It appears that the 
physiological role of the two distinct alternative splice forms of LKB1 is not directly 
connected to divergences in the carboxyl terminal sequences but probably because 
of differences in tissue distribution 
41. In order to be active, it is essential also for 
LKB1 to form a heterotrimeric complex with two regulatory subunits, namely the 
pseudokinase STE20-related adaptor protein α (STRADα) and Mouse protein 25 
(MO25) 
42-43. AMPK activity is significantly reduced in a tissue-specific knockout 
model of LKB1 in myocytes, cardiocytes and hepatocytes indicating that LKB1 
plays a key role in AMPK activation 
44-46.  
   20
 
Figure 1.3: Regulation of AMPK: LKB1 and CaMKKβ activate AMPK by 
phosphorylation at Thr-172. AMP allosterically activates AMPK and also protects 
the activation loop from dephosphorylation by protein phosphatases. 
 
CaMKKs were initially shown to phosphorylate Calmodulin-dependent protein 
kinases I and IV 
47. Their physiological role as an activator of AMPK was revealed 
when in HeLa cells, which do not express LKB1, the basal activity of AMPK was 
diminished by the CaMKK inhibitor STO-609. In contrast, when incubated with the 
Ca
2+ ionophore A23187, AMPK activity increased 
39. Two isoforms of CaMKK, 
which are primarily found in neural tissue, have been identified, α and β, but it was 
shown that only CaMKKβ, plays a major role in phosphorylating and activating 
AMPK in vitro and in mammalian cells 
39,48-49. Hence, there appear to be at least two 
signaling pathways that trigger AMPK activity, one dependent on LKB1 and the 
other induced by increases in calcium, mediated by CaMKKβ. 
 
Recently, it has been reported that transforming growth factor-β-activated kinase-1 
(TAK1) activates AMPK in rodents, but the physiological role of TAK1 as an 
AMPKK is not well documented 
50-51. Further, auto-phosphorylation on the α and β 
subunits may additionally affect enzymatic activity 
52-53, but their precise role is also 
still unclear. It has been suggested that these additional auto-phosphorylation sites 
might play a role in AMPK activity or cellular localization.  
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AMPK is down-regulated when de-phosphorylated by a protein phosphatase (PP). 
The identity of the protein phosphatase responsible for AMPK dephosphorylation in 
vivo has not been determined. Although all the PP tested de-phosphorylated AMPK 
in vitro, the likely physiological candidates are PP2A and PP2C (the latter is also 
referred as PPM) 
54. The yeast homologue of AMPK, SNF1 complex has been 
shown to be de-phosphorylated by the Glc7-Reg1 protein phosphatase complex 
55. 
Glc7 is the catalytic subunit of the complex and belongs to the type I PPs (PP1) 
56. 
Reg1 interacts with the catalytic subunit of the SNF1 complex, Snf1, leading to the 
inactivation of SNF1 complex through dephosphorylation of the activation loop by 
Glc7. By analogy this suggests that PP1 might play a role in the regulation of 
mammalian AMPK, although this issue has yet to be confirmed.   
 
Mutation of Thr-172 to a negatively charged residue such as a glutamic acid 
(Thr-172ÆGlu) can, to some extent, mimic the phosphorylation event  resulting in 
constitutive activity that is about 50% of the corresponding activated wild-type 
AMPK 
57. Conversely, mutation of Thr-172 (Thr-172ÆAla), abolishes AMPK 
activity almost entirely.  
 
 
AMPK phosphorylates, and differentially regulates numerous targets. Some of these 
include: acetyl-CoA carboxylase 1 (ACC1), HMG-CoA reductase (HMGR) and 
muscle glycogen synthase (GS) phosphorylation of which inactivates the synthesis 
of fatty acid, cholesterol and glycogen, respectively (Table 1.1) 
4,58-60.  AMPK also 
inhibits protein synthesis in different ways, either by activating elongation factor-2 
kinase (EF-2 kinase) 
61, therefore inhibiting the elongation step, or by inhibiting the 
mammalian target of rapamycin (mTOR), which enhances translational initiation. 
mTOR is inhibited by AMPK either directly, by phosphorylating the mTOR binding 
partner, raptor, or by phosphorylating Tuberus Sclerosis complex 2 (TSC2) which 
lies upstream of mTOR 
62-65.  
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Other AMPK targets include proteins involved in the production of energy such as 
acetyl-CoA carboxylase 2 (ACC2), 6-phosphofructo-2-kinase (PFK2), hormone-
sensitive lipase (HSL), fatty acid translocase (FAT/CD36). Their phosphorylation 
enhances fatty acid oxidation, glycolysis, triglyceride breakdown and fatty acid 
uptake, respectively (Table 1.1) 
23,66-72. AMPK also enhances glucose uptake by 
enabling the translocation of GLUT4 vesicles. This appears to be mediated by 
AMPK by targeting the Akt Substrate 160 (AS160), although recently it has been 
suggested that AS160 is not directly phosphorylated by AMPK but TBC1D1 appears 
to be the true downstream substrate for AMPK (explained in more detail in section 
1.1.4.1) 
71,73-75. 
 
AMPK therefore plays a dual role in re-establishing cellular energy homeostasis by 
the inhibition of ATP-consuming processes and by enhancing ATP-producing 
pathways. In addition, AMPK also exerts long-term effects on fatty acid synthesis 
and gluconeogenesis altering gene expression 
76-78 and  these effects are probably 
mediated by down-regulating transcription factors such as HNF-4α or GLUT4 
79-80. 
GLUT4 expression in myocytes, for example, is enhanced by AMPK by stimulating 
the binding of the transcription factor myocyte enhancer factor-2 (MEF-2) to the 
GLUT4 promoter 
80. Alternatively, AMPK exerts its effects at the transcriptional 
level by directly phosphorylating transcriptional coactivators such as PPAR-γ 
coactivators-1α (PGC-1α; 
81), at Thr-177 & Ser-538, or as transducer of regulated 
CREB activity 2 (TORC2; 
82), at Ser-171. AMPK phopshorylation of PGC-1α 
results in upregulation of several transcription factors involved in mitochondrial 
biogenesis 
83, whereas phosphorylation of TORC2 by AMPK results in a reduction 
in gluconeogenesis by blocking its nuclear accumulation 
82. 
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71; 74 ↑ glucose uptake Ser-588 AS160
73-75 ↑ glucose uptake Ser-231; Ser-660; 
Ser-700 
TBC1D1
81; 83 ↑ mitochondrial biogenesis Thr-177; Ser-538 PGC-1α
23 ↑ glycolysis  Ser-466 PFK-2
64 ↓ protein synthesis Thr-1227; Ser-1345  TSC2
61 ↓ protein synthesis Ser-366; Ser-398 EF-2 kinase
ATP-producing pathways
66; 70 ↑ fatty acid oxidation  Ser-222 ACC2
67; 68 ↑ triglyceride breakdown Ser-565 HSL
69 ↑ fatty acid uptake FAT/CD36
↓ gluconeogenesis
↓ protein synthesis
↓ glycogen synthesis
↓ fatty acids synthesis 
↓ cholesterol synthesis 
Effect on activity/Role
82
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58; 60
59
4; 59
Ref
Ser-171 TORC2
Ser-722; Ser-792 Raptor
Ser-7 GS
Ser-79; Ser-1200; 
Ser-1215
ACC1
Ser-871 HMGR
ATP-requiring pathways
Residue Substrate
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Table 1.1: Downstream targets of AMPK: the phosphorylation sites are shown 
together with the effect on metabolism. 
 
 
1.1.2.2 Regulation of AMPK by AMP 
The binding of a ligand to a site on a protein, that is not the active site, which alters 
enzyme activity is termed allosteric regulation. Such ligands may enhance the 
activity of the enzyme and be referred to as allosteric activators, or they may 
decrease the enzyme’s activity and are described as allosteric inhibitors 
84. Allosteric 
regulation can occur within one subunit or between subunits. AMP-activated protein 
kinase was so-named because early studies showed that this protein kinase was 
allosterically activated by AMP 
85. AMPK purified from rat tissues was shown to be   24
activated by AMP around 3-fold in vitro. Later it was shown that AMP bound to the 
regulatory γ subunit and that the level of activation depended on the combination of 
isoforms making up the heterotrimer 
86. Specifically, AMPK containing a γ2 subunit 
is more sensitive to AMP than γ1- or γ3-containing heterotrimers; γ3 being the least 
AMP responsive. Neither ADP and ATP allosterically activate AMPK but bind to 
the AMP site, thus by competing with AMP, ATP inhibits activation of AMPK.  
 
AMP also acts to protect AMPK from dephosphorylation of Thr-172 
5,54 (Fig 1.3). 
Initially it was believed that AMP facilitated a third mechanism for AMPK 
activation by promoting phosphorylation of Thr-172. However, a recent paper has 
suggested that initial data were misinterpreted because AMPK samples were only 
partially purified and some PP2C was present in the preparation 
87.  
 
5-aminoimidazole-4-carboximide ribonucleoside (AICAR) has been a valuable tool 
for studying AMPK regulation in cells 
4. AICAR is an adenosine analogue that 
enters the cells via adenosine transporters 
88. It is then converted by adenosine kinase 
to 5-aminoimidazole-4-carboximide riboside monophosphate (ZMP), by the addition 
of a phosphate group 
89 (Fig 1.4). ZMP mimics both of the effects of AMP on 
AMPK (i.e. allosteric activation and reduced dephosphorylation), but its potency is 
poorer than AMP 
59,90. Additionally, this compound is not completely specific for 
AMPK, as ZMP interacts with other AMP-sensitive enzymes such as 
fructose-1,6-bisphosphatase (FBPase) and muscle glycogen phosphorylase 
89,91 (see 
section  1.1.3.3). 
                     
Figure 1.4: Structure of AICAR (left) which is converted to ZMP (right) by 
adenosine kinase. 
Adenosine kinase 
HO   25
 
1.1.2.3 Putative allosteric inhibition of AMPK by glycogen  
Previous studies have shown connections between AMPK and glycogen metabolism 
30. Among the downstream targets of AMPK is glycogen synthase, which is 
responsible for the synthesis of glycogen from glucose-6-phosphate. The synthesis 
of glycogen is a process that requires larges amount of energy, therefore when there 
is high utilization of ATP, AMPK phosphorylates glycogen synthase, inhibiting its 
activity, leaving the metabolized glucose free to enter glycolysis 
58,92. An additional 
connection between AMPK and glycogen metabolism is shown in myocytes, where 
high glycogen levels repress contraction-induced AMPK activation 
92-93. 
Interestingly, naturally occurring mutations in the human γ2 subunit of AMPK 
causes a glycogen storage cardiomyopathy. 
 
Recently, McBride and Hardie suggested that AMPK might play a direct role in 
glycogen storage and utilization, by acting as a glycogen storage sensor 
94. As 
mentioned above, the β subunit of AMPK contains a GBD. The GBD has been 
proposed to regulate AMPK activity in response to cellular glycogen content. 
Specifically, McBride and Hardie proposed that glycogen could allosterically inhibit 
AMPK. This might explain why, in response to exercise, high glycogen levels in 
myocytes reduce AMPK activity without apparently changing adenine nucleotide 
concentration 
92. McBride and Hardie additionally suggested that glycogen inhibited 
the phosphorylation of Thr-172 phosphorylation of AMPK by upstream kinases 
94. 
 
 
1.1.2.4 Regulation by hormones and cytokines 
AMPK is also involved in the regulation of whole-body energy metabolism as it 
regulates both energy expenditure and appetite. AMPK activity in different tissues is 
coordinated via the secretion of various hormones and cytokines. For example, 
adipocytes secrete hormones such as leptin, adiponectin and resistin, whereas 
stomach cells secrete ghrelin 
95. Cytokines such as interluekin-6 (IL-6), ciliary   26
neurotrophic factor (CNTF) and tumor necrosis factor α (TNF- α) are also secreted 
by specific cells of the immune system 
95. Leptin and adiponectin appear to enhance 
insulin sensitivity by influencing weight gain, feeding behavior and glucose 
homeostasis. Activation of AMPK by these hormones in peripheral tissues causes an 
increase in fatty acid oxidation and an increase in glycolysis (Table 1.2) 
96-97. Leptin 
and adiponectin are unable to regulate glucose homeostasis in the livers of AMPK 
knock-out mice, suggesting that these effects may be partly mediated by AMPK 
activation 
98. Additionally, expression of a dominant negative mutant of AMPK 
using an adenoviral vector lead to a reduction of gluconeogenesis in the liver, and 
reduction of glucose levels in vivo, confirming that stimulation of glucose utilization 
and fatty-acid oxidation by adiponectin occurs via AMPK activation 
97. 
 
While leptin and adiponectin appear to enhance insulin sensitivity, other hormones 
and cytokines seem to have the opposite effect on insulin sensitivity 
95,99-102. For 
example, the level of AMPK phosphorylation in the liver of resistin knock-out mice 
is higher compared to wild type, indicating that resistin might down-regulate hepatic 
AMPK 
103. It is thought that inappropriate secretion of these hormones and cytokines 
play an important role in the development of obesity and metabolic syndrome 
95. 
Therefore it will be important to determine the exact roles of AMPK in influencing 
the effects brought about by these hormones and cytokines, and to understand the 
connection between AMPK and whole energy homeostasis.   27
? ↓ ? TNF- α
↑ ↑ ? IL-6
Cytokines
↓ ↓ ? Resistin
↓ no effect ↑ Ghrelin
↑ ↑ ↑ Adiponectin
↑ ↑ ↓ Leptin
Hormones
Adipocytes Skeletal muscles Hypothalamus
? ↓ ? TNF- α
↑ ↑ ? IL-6
Cytokines
↓ ↓ ? Resistin
↓ no effect ↑ Ghrelin
↑ ↑ ↑ Adiponectin
↑ ↑ ↓ Leptin
Hormones
Adipocytes Skeletal muscles Hypothalamus
 
Table 1.2: Summary of the effects of hormones and cytokines on AMPK activity in 
three different tissues. This is consistent with a crucial role of AMPK in regulating 
whole body energy homeostasis. 
 
1.1.3 AMPK across the kinome 
1.1.3.1 AMPK-related kinases (AMPK-RK) 
Sequence homology analysis has revealed thirteen human protein kinases closely 
related to the catalytic subunit of AMPK that are referred to as the AMPK-RK 
family. They comprise: BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, 
MELK, NUAK1, NUAK2, QIK, QSK, SIK and SNRK 
104 (Fig 1.5). Like AMPK 
they are regulated via phosphorylation of a threonine residue on their activation 
loops by LKB1. The specificity of these AMPK-RK to the upstream activation is 
somewhat different to AMPK in that the activation loops contains a leucine residue 
at the -2 position 
46. Interestingly, AMPK-RK do not appear to be regulated by 
CaMKKs. For some of them, phosphorylation enhances their activity as much as 
50-fold 
105. In contrast, MELK is the only protein of this family that is not 
phosphorylated by LKB1 but is instead activated by auto-phosphorylation 
105. SNRK 
is the least conserved member of the AMPK-RKs and belongs to an additional 
family of 8 protein kinases, referred to as the SNRK family 
106. Interestingly, only 
SNRK from this group is activated by LKB1 possibly because it is the only protein   28
among the SNRK family that contains a leucine at the -2 position in the activation 
loop.  
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Figure 1.5: LKB1 is the master regulator of 13 protein kinases. The activity and 
cellular localization of LKB1 is controlled through its interaction with STRAD and 
MO25. α, the catalytic subunit of AMPK, is related to AMPK-RK and SNRK. 
MELK, although belongs to AMPK-RK, is not activated by LKB1 but by 
auto-phosphorylation. The SNRK family comprises NIM1, TSSK1, TSSK2, TSSK3, 
TSSK4, SSTK, HUNK and SNRK. Only the latter is phosphorylated by LKB1. 
 
The sequences of the α subunit of AMPK and AMPK-RKs, are similar and all 
contain an amino-terminal kinase domain. Except for NUAK-1 & -2, the kinase 
domain of AMPK-RK is followed by an ubiquitin-associated (UBA) domain. A 
UBA domain is a sequence of about 45 amino acid residues present in various 
enzymes, although the AMPK-RKs are the only family of kinase proteins in the 
human genome to contain a UBA domain 
104,107. In proteins other than kinases, UBA 
domains function as ubiquitin- or polyubiquitin-interacting motifs, whereas in 
AMPK-RKs they do not interact with ubiquitin-like molecules, but appear to be 
necessary for LKB1 phosphorylation 
104,106,108. The effect of UBA domains in 
AMPK-RK is achieved not by associating with the LKB1–STRAD–MO25 complex,   29
but by directly interacting with the catalytic domain of these AMPK-RKs, 
facilitating an optimal conformation for phosphorylation by LKB1 
107. 
 
1.1.3.2 Yeast homologues of AMPK 
AMPK is highly conserved across species and many insightful studies have been 
carried out on the yeast homologue of AMPK, SNF1 from S. Cerevisiae 
6. 
Homologues of the mammalian α, β and γ subunits are present in S. Cerevisiae. Snf1 
is the catalytic subunit that contains the kinase domain; Sip1, Sip2 and Gal83 
proteins are scaffolding subunit equivalent to β 
109, and Snf4 corresponds to the 
γ subunit and contains four CBS motifs. Interestingly, SNF1 is not AMP regulated 
but it performs the role of cellular energy monitor by phosphorylating targets 
involved in the regulation of gene transcription in response to intracellular changes 
in glucose levels 
110. No full-length structures have been solved for SNF1, but 
truncated constructs, similar to the one used in our lab, have been crystallized (see 
section 3.2.2). The structure of the kinase domain alone of Snf1, was solved in 2005 
at about the same time as the human α2 AMPK kinase domain 
111. The crystal 
structure of the regulatory domain of SNF1, and of the SNF1 protein from S. 
Cerevisiae, were both published in 2007, at the same time as our mammalian 
version. These structures showed similar domain arrangement as ours and, 
additionally, the SNF-like protein contained a GBD which interacts with the 
γ subunit equivalent 
112-113 (see section 5.6).  
 
 
1.1.3.3 Other AMP-regulated enzymes 
AMPK is not the only AMP-dependant enzyme in mammalian cells. The widespread 
use of AICAR in AMPK studies revealed that other AMPK-independent pathways 
are affected. Further studies with liver specific AMPK knock-out mice 
(AMPKα1α2
−/−) demonstrated that AICAR inhibited glucose-induced translocation 
of glucokinase from the nucleus 
114. In liver cells from AMPKα1α2
−/− mice AICAR 
also inhibited cellular respiration in association with a decrease in cellular ATP 
concentrations 
115. This inhibition resulted partly from an ATP-mediated   30
phosphorylation of AICAR which leads to a reduction in intracellular phosphate, 
which is one of the main cofactors in mitochondrial oxidative phosphorylation 
(OXPHOS) 
115. ZMP accumulation also affects many enzymes with AMP-binding 
sites, such as glycogen phosphorylase, glycogen synthase, or fructose 1,6-
bisphosphatase, glucokinase and phosphofructokinase-1 
89,91,116-118, their respective 
Kms for ZMP being generally in the range of the cellular nucleotide concentration. 
These results clearly show that some of the effects of AICAR in cells are not caused 
by AMPK and the results that come with its use need to be carefully interpreted. 
 
Glycogen phosphorylase (GP) is a good example of a structurally well documented 
enzyme whose activity is regulated by AMP (Fig 1.6). Glycogen phosphorylase 
catalyses the first step of glycogenolysis which is the intracellular degradation of 
glycogen into glucose-1-phosphate 
119. It exists in a non-phosphorylated GPb form 
(T state) which is less active and in an active phosphorylated form GPa (R state) 
120. 
Hormonal or neuronal signals stimulate the phosphorylation on a serine residue at 
the amino terminal (Ser-14) located on the surface of the protein. The 
non-phosphorylated form of glycogen phosphorylase is also allosterically activated 
by micromolar concentrations of AMP and the level of activity achieved by 
phosphorylation and allostery are comparable 
119. Therefore, during physical 
exercise for example, AMP concentration increases and glycogen phosphorylase is 
allosterically activated. By enhancing glycolysis, glycogen phosphorylase enhances 
ATP supply. Consequently, ATP opposes the allosteric activation by displacing 
AMP from the binding pocket. This indicates the re-establishment of energy 
homeostasis.   31
 
 
Figure 1.6: Cartoon representation of glycogen phosphorylase in the R state (PDB: 
7GPB). In the unbound state, the non-phosphorylated form of glycogen 
phosphorylase is a dimer. (A) Once AMP binds, or the enzyme is phosphorylated, 
two dimers associate to produce a tetramer. (B) Superposition between the R state 
(protein colored in orange with AMP in sticks with carbon atoms in magenta) and T 
state (protein in cyan with AMP in sticks with carbon atoms in yellow – PDB: 
8GPB). Arg-43 belongs to the other subunit of the enzyme which is in red). 
 
 
When non-phosphorylated, glycogen phosphorylase has low affinity for substrates, 
but when phosphorylated the affinity for substrates and allosteric activators increases 
119. The catalytic site is at the centre of the protein distinct from the surface where 
AMP binds at the interface of the two subunits. The low affinity of AMP for the T 
state can be structurally explained by the relatively few contacts formed between the 
phosphate moiety of the nucleotide and two basic residues in the allosteric binding 
pocket (Arg-309 & Arg-310). Thus the specificity for ligand binding arises from 
other parts of the nucleotide, hence other ligands such as ADP, ATP, ZMP can also 
bind 
121. When non-phosphorylated, the N-terminal part containing Ser-14 blocks 
access to the catalytic site. But, in the R state, once Ser-14 is phosphorylated it shifts 
approximately 34 Å and it interacts with two other basic residues at the subunit 
interface (Arg-69 from one subunit & Arg-43’ from the other) and liberates the 
catalytic site 
122. This causes AMP to shift a few Å and its ribose and adenosine 
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moiety form new interactions with the protein. This binding site therefore becomes 
more extensive following phosphorylation creating a more favorable binding site for 
AMP.  
 
Another example, in less detail, of an enzyme which is regulated by AMP is fructose 
FBPase (Fig 1.7). FBPase catalyzes an important step of gluconeogenesis by 
hydrolyzing fructose-1,6-bisphosphate (F-1,6-P2) to fructose-6-phosphate and 
inorganic phosphate 
123. FBPase is very sensitive (micromolar range) to allosteric 
inhibition by AMP and its believed to be constantly inhibited in the presence of 
normal physiological AMP concentrations 
124. In contrast, when, glyconeogenesis or 
gluconeogenesis is needed, the substrate for FBPase is supplied by aldolase. In 
myocytes, aldolase strongly interacts with FBPase forming a complex which is then 
insensitive to AMP 
125.  
 
 
Figure 1.7: Surface representation of the dimeric complex of two FBPases (PDB: 
1FPF). Mammalian FBPase exists as a tetramer where each monomer is composed 
of two domains, the F-1,6-P2 domain containing the active site and AMP-binding 
site domain 
126. AMP and 2,5-anhydroglucitol-1,6-biphosphate (an 
F-1,6-P2-analogue) are shown in sticks with carbon atoms colored in cyan and 
magenta, respectively. 
AMP   33
 
Similarly to AMPK, misregulation of the activity of glycogen metabolism enzymes 
may result in defects leading to glycogen storage diseases (GSD) 
127 (see section 
1.1.4.3). There are eleven distinct conditions that are commonly considered to be 
glycogen storage diseases and malfunction in the activity of glycogen synthase, 
muscle glycogen phosphorylase, liver glycogen phosphorylase and muscle 
phosphofructokinase-1 correspond to GSD types 0, 5, 6 and 7, respectively. 
 
 
 
 
1.1.4 Connection to diseases 
As AMPK is implicated in the regulation of food intake and energy expenditure at 
the systemic level, it is considered a promising target for the treatment of metabolic 
disorders including cardiovascular disease, obesity, type II diabetes and, recently, 
cancer. Additionally, AMPK regulation is linked to other human disorders as 
naturally occurring mutations in its γ subunit are also responsible for 
Wolff-Parkinson-White (WPW) syndrome. 
 
1.1.4.1 Diabetes mellitus 
The World Health Organisation (WHO) estimates that more than 180 million people 
worldwide have diabetes and this number is increasing rapidly. Approximately 1.1 
million people died from diabetes in 2005 and this number is projected to increase 
by over 50% in the next 10 years. 10% of the cases of diabetes mellitus belong to 
type I, whereas 90% are attributed to type II 
128. The former type is more acutely 
life-threatening than the type II form and is characterized by insulin deficiency due 
to autoimmune destruction of β-cells from the pancreas which secrete it. It has an 
early onset and is treated with insulin injections. Type II diabetes instead has an 
adult-onset and, although there seems to be genetic factors that influence 
predisposition, it is strongly associated with a sedentary lifestyle and an unbalanced   34
diet. Both forms, if untreated lead to long-term complications, including retinal 
damage, nerve damage and kidney & cardiovascular disease 
128-129.  
 
Type II diabetes is associated with increased insulin, glucose and lipid 
concentrations in the blood together with insulin resistance of tissues. Patients have 
reduced glucose uptake in peripheral tissues and increased gluconeogenesis. Cellular 
glucose uptake is mediated by glucose transporters (GLUTs) of which thirteen 
isoforms are currently known, and their relative abundance is tissue-specific 
130. 
GLUT4 is mostly found in skeletal muscles and adipose tissues, which together 
comprise about 60% of body mass 
131. One of the main cellular effects of insulin is 
to stimulate glucose uptake from the blood into cells following a carbohydrate-rich 
meal by mediating the translocation of GLUT4 to the plasma membrane 
132. Diabetic 
patients have a dysfunctional insulin pathway that leads to poor GLUT4 
translocation to the plasma membrane 
132. However, a parallel, insulin-independent, 
pathway for glucose uptake can still be activated via physical exercise which mimics 
some of the cellular effects of insulin 
29,133 (Fig 1.8). One of the key players in the 
exercise-induced GLUT4 recruitment is AMPK 
134-135. Numerous studies showed 
that the exercise-induced pathway is insulin-independent as incubation with 
wortmannin, an inhibitor of PI3-Kinase (a kinase triggered by insulin), does not 
block this pathway 
136. Additionally, the insulin-induced and exercise-induced 
glucose uptakes are additive 
137. The two pathways converge at the point where the 
protein TBC1D1 is phosphorylated. This protein is involved in regulating GLUT4
 
translocation 
138. Interestingly, when glucose uptake is triggered by AMPK 
activation, the glucose is destined for glycolysis/oxidation, whereas when insulin 
stimulated, the sugar is destined for glycogen synthesis 
139.  
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Figure 1.8: Two parallel signaling pathways exist which mediate glucose uptake in 
skeletal and adipose tissues. One of these two pathways is insulin-dependent and the 
other is exercise-induced. (A) Following a carbohydrate-rich meal the blood has 
increased levels of glucose. When insulin binds to the insulin-receptor a cascade of 
signals lead to the translocation of GLUT4 transporters to the plasma membrane. (B) 
Glucose can then enter into the cell. (C) In diabetic patients, where insulin signalling 
is compromised, glucose remains in the blood, reaching toxic levels which are 
responsible for the symptoms of the disease. (D) AMPK, via an exercise-induced 
mechanism, also leads to the phosphorylating of AS160, enhancing GLUT4 
recruitment. (E) Glucose can now enter the cell via this alternative mechanism 
which is insulin-independent 
139. 
 
 
Some of the most widely prescribed diabetic drugs are the thiazolidinediones (e.g. 
rosiglitazone and pioglitazone) and biguanide (e.g. phenformin and metformin) 
140-
144. Although AMPK was not the primary target of the study, these drugs have been 
found to activate AMPK, leading to the identification of the enzyme as a good 
potential target for the treatment of diabetes. Since these drugs have been reported to 
have undesirable side effects such as heart failure and lactic acidosis they had to be 
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withdrawn from the market 
145-148. In contrast, although metformin causes 
gastrointenstinal upset, it remains the most widely prescribed drug for type II 
diabetes. Metformin is an oral drug which improves insulin sensitivity in type II 
diabetic patients, and decreases plasma glucose and lipids by decreasing 
gluconeogenesis and, to a minor extent, by increasing glucose uptake into skeletal 
muscle 
149-150. These effects appear to be mediated via hepatic AMPK activation by 
inhibiting the mitochondrial respiratory complex. This in turn causes inhibition of 
mitochondrial respiration and inhibition of β-oxidation of fatty acids 
151-153.  
 
However, all these drugs activate AMPK indirectly and have only modest potency. 
One of the aims of current research is to find a drug that directly and potently 
activates AMPK. This approach might combine therapeutic benefits while 
eliminating unwanted side effects.  
 
In 2006, Cool et al discovered a small molecule activator of AMPK, A-769662, a 
compound from the thienopyridone family, which is conventionally referred to as 
Abbott compound (from the name of the labs where it was synthesized) 
154. 
Although A-769662 is thought to bind directly to AMPK, its binding site has not 
been identified. A-769662 is not an AMP mimetic, though it produces the same 
effects as AMP, i.e. allosteric activation and protection against dephosphorylation. 
As a consequence it is more specific than AICAR, as it does not affect fructose-1,6-
bisphosphatase or glycogen phosphorylase 
154. Unfortunately, the therapeutic use of 
A-769662 is not promising as it has a poor oral absorption 
154-155, therefore there is a 
strong impetus to identify a direct, specific and potent activator of AMPK that has 
good pharmokinetic properties. 
 
 
1.1.4.2 Cancer 
The role of AMPK as a potential target to treat diabetes is well established, but in 
these last few years AMPK has been revealed as a potential target for cancer 
treatment. Its involvement in cancer incidence was noted when patients who were   37
treated with metformin (section 1.1.4.1) were found to have a decreased rate of 
cancer compared with untreated patients 
156. It has been shown that breast cancer cell 
growth is inhibited by metformin in an AMPK-dependent way and by 
down-regulating the mammalian target of rapamycin (mTOR) activity 
157-158. mTOR 
is a major player in cell growth and proliferation, which is over-activated in many 
different types of cancer 
159. The mTOR signaling pathway is triggered in response 
to growth factors, such as insulin and insulin-like growth factor, and it mediates 
ribosomal biogenesis and protein translation 
160. Since processes such as protein 
synthesis require larges amount of energy, increases in cellular AMP/ATP ratio lead 
to an AMPK inhibition of mTOR signaling. AMPK indirectly inhibits mTOR by 
activating the TSC1/TSC2 heterodimer, a complex between two tumor suppressors 
that lie upstream of mTOR 
161. More precisely, TSC2 is phosphorylated at Ser-1345 
and it appears to activate the GTPase-activating protein activity of TSC2 towards 
Rheb, a Ras family GTPase that activates mTOR complex 1 (mTORC1) 
64,162. Thus, 
Rheb-GTP levels, and therefore mTOR activity, are decreased. It has been recently 
shown that AMPK inhibits mTOR signaling by an alternative pathway by directly 
phosphorylating Raptor, a subunit of TORC1, at Ser-722 and Ser-792 which are two 
phosphorylation sites important for the down-regulation of mTORC1 
63.  
 
Other evidence that supports a role for AMPK in human cancer is that the tumor 
suppressor LKB1 is itself involved in different types of cancer 
161. Impaired LKB1 
activity is not only implicated for Peutz–Jeghers syndrome but is also responsible for 
pancreatic and biliary cancers, malignant melanomas, human non-small cell lung 
cancer and other lung cancer cell lines 
163-167. Additionally, in humans, LKB1 is 
involved in cell polarity, another energy-consuming process whose deregulation is 
often linked to tumor invasion 
42-43. Studies in Drosophila have showed that deletion 
of either AMPK or LKB1 produced a similar phenotype; disrupted cellular structure 
& cell polarity, suggesting that the effects of LKB1 in cell polarity are, at least in 
part, mediated by AMPK 
168-169. More specifically, AMPK plays a key role in the 
regulation of epithelial tight junction assembly and trans-epithelial resistance 
through activation of a calcium switch which prevents tight junction disassembly   38
170-171. The molecular mechanisms and phosphorylation events involved in this 
process are unclear. 
 
 
1.1.4.3 Wolff-Parkinson-White (WPW) syndrome 
Naturally occurring mutations in the human γ2 isoform of AMPK, encoded by the 
PRKAG2 gene, causes a cardiomyopathy characterized by a marked accumulation of 
glycogen in cardiac muscle cells. A mutation in the γ3 subunit of AMPK in 
Hampshire pigs is associated with elevated glycogen content in skeletal muscles 
172. 
Interestingly, no natural mutations in the γ1 subunit have been identified, 
presumably because they would be embryonically lethal since the γ1 isoform 
provides the majority of AMPK activity in most cell types 
173. The mutations found 
in the γ2 subunit comprise one insertion of a leucine residue between Arg-350 and 
Glu-351 and ten missense mutations (Arg302Gln, Leu351Ins, His383Arg, 
Arg384Thr, Thr400Asn, Asn488Ile, Tyr487His, Glu506Lys, Arg531Gly, 
Arg531Gln and Ser548Pro (Table 1.3) 
174-183.  
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182 Possible Y Adult 1 (1) Ser548Pro
179 Y Y Neonatal 3 (3) Arg531Gln
180 Y N Paediatric 4 (1) Arg531Gly
177 - Y Adult 8 (1) Glu506Lys
176 Y Y Juvenile 2 (1) Tyr487His
175 Rare Y Adolescence  
to Adult
40 (1) Asn488Ile
175 - Y Adult 1 (1) Thr400Asn
174 - Y Paediatric 1  Arg384Thr
178 - Y Paediatric 3 (1) His383Arg
178 Common Y Adult 5 (1) Leu351Ins
175,180 Y Y Adolescence  
to Adult
78 (8) Arg302Gln
Reference
Sudden 
cardiac 
death
Left 
ventricular 
hypertrophy
Age of onset
No. of 
patients 
(families)
Mutation
182 Possible Y Adult 1 (1) Ser548Pro
179 Y Y Neonatal 3 (3) Arg531Gln
180 Y N Paediatric 4 (1) Arg531Gly
177 - Y Adult 8 (1) Glu506Lys
176 Y Y Juvenile 2 (1) Tyr487His
175 Rare Y Adolescence  
to Adult
40 (1) Asn488Ile
175 - Y Adult 1 (1) Thr400Asn
174 - Y Paediatric 1  Arg384Thr
178 - Y Paediatric 3 (1) His383Arg
178 Common Y Adult 5 (1) Leu351Ins
175,180 Y Y Adolescence  
to Adult
78 (8) Arg302Gln
Reference
Sudden 
cardiac 
death
Left 
ventricular 
hypertrophy
Age of onset
No. of 
patients 
(families)
Mutation
 
Table 1.3: List of mutations that have been identified to date in the human AMPK 
γ2 subunit that give rise to WPW syndrome.  
 
The data in the literature regarding the effects of these mutations on AMPK activity 
are incomplete, unclear and sometimes contradictory (summarized in Table 1.4). 
Overexpression studies in pulmonary fibroblasts and COS cells showed that by 
mutating the equivalent of γ2-Arg302Gln in γ1 and γ3 (Arg70Gln and Arg225Gln, 
respectively) resulted in the basal activity of AMPK being increased but sensitivity 
to AMP was impaired 
184-185. In contrast, studies performed with CCL13 cells with 
Arg302Gln, His383Arg, Thr-400Asn and Arg531Gly displayed a reduced AMPK 
activity 
16,186. Interestingly, in the same study, the insertion of a leucine (Leu351-Ins) 
had no effect on AMP sensitivity and enzyme activity. It has been suggested that the 
discrepancies in these results arises because of the different cell lines used, which 
contain different amounts of LKB1 
179. Subsequent to submission Hawley et al 
published some results using stably transfected isogenic cell lines, the effect of 
which could be quantified in a more reliable manner. They showed that although the 
expression levels of the wild type and Arg531Gln mutant of AMPK were identical, 
the mutant was insensitive to AMP but had a 2-fold higher basal activity 
187.    40
 
Transgenic mice overexpressing tissue-specific AMPK-γ2 have also been employed 
188-189. The heart-specific mutant animals expressing Arg302Gln, Asn488Ile, 
Thr400Asn or Arg531Gly displayed cardiac hypertrophy and increased glycogen 
storage 
190-193. Interestingly the mutations affecting the basic residues (Arg302Gln & 
Arg531Gly) resulted in decreased AMPK activity, whereas the Asn488Ile and 
Thr400Asn  mutations displayed increased activity and biphasic changes in activity, 
respectively (Table 1.4). 
16; 184 CCL13 ↓ activity; ↓ AMP stimulation
187 HEK293 ↑ Basal activity; ↓ AMP stimulation γ2 Arg531Gly
16 CCL13 ↓ activity; ↓ AMP stimulation γ2 Thr400Asn
16; 186 CCL13 ↓ activity; ↓ AMP stimulation γ2 His383Arg
16; 186 CCL13 No effect γ2 Leu351ins
180 COS7 ↑ Basal activity; ↓ AMP stimulation γ3 Arg225Gln
16; 186  CCL13 ↓ activity; ↓ AMP stimulation γ2 Arg302Gln
185 COS7 ↑ Basal activity; ↓ AMP stimulation γ1 Arg70Gln
Cell type Overexpression in cells
188 ↑ Muscle glycogen γ1 Arg70Gln
189 ↑ Muscle glycogen
↑ activity and ↓ AMP stimulation
γ3 Arg200Gln
Trangenic (muscle)
192 Cardiac hypertrophy, glycogen storage
↓ activity and AMP stimulation
γ2 Arg531Gly
191 Cardiac hypertrophy, glycogen storage
Biphasic changes in activity
γ2 Thr400Asn
190 Cardiac hypertrophy, glycogen storage ↑ activity γ2 Asn488Ile
193 Cardiac hypertrophy, glycogen storage ↓ activity γ2 Arg302Gln
Trangenic (heart)
184 Impaired glycogen synthesis after 
exercise
γ3 KO
Whole body knockout
Reference Phenotype Subunit
16; 184 CCL13 ↓ activity; ↓ AMP stimulation
187 HEK293 ↑ Basal activity; ↓ AMP stimulation γ2 Arg531Gly
16 CCL13 ↓ activity; ↓ AMP stimulation γ2 Thr400Asn
16; 186 CCL13 ↓ activity; ↓ AMP stimulation γ2 His383Arg
16; 186 CCL13 No effect γ2 Leu351ins
180 COS7 ↑ Basal activity; ↓ AMP stimulation γ3 Arg225Gln
16; 186  CCL13 ↓ activity; ↓ AMP stimulation γ2 Arg302Gln
185 COS7 ↑ Basal activity; ↓ AMP stimulation γ1 Arg70Gln
Cell type Overexpression in cells
188 ↑ Muscle glycogen γ1 Arg70Gln
189 ↑ Muscle glycogen
↑ activity and ↓ AMP stimulation
γ3 Arg200Gln
Trangenic (muscle)
192 Cardiac hypertrophy, glycogen storage
↓ activity and AMP stimulation
γ2 Arg531Gly
191 Cardiac hypertrophy, glycogen storage
Biphasic changes in activity
γ2 Thr400Asn
190 Cardiac hypertrophy, glycogen storage ↑ activity γ2 Asn488Ile
193 Cardiac hypertrophy, glycogen storage ↓ activity γ2 Arg302Gln
Trangenic (heart)
184 Impaired glycogen synthesis after 
exercise
γ3 KO
Whole body knockout
Reference Phenotype Subunit
 
Table 1.4: Genetic models of mutant AMPK that have been generated to date. 
Knock-out (KO) and overexpression of mutants of AMPK have been used to study 
their effects in vivo and in cells. In transgenic mice the same phenotype is observed 
as in human patients with cardiac hypertrophy and increased cardiac glycogen 
stores.   41
 
Overall it can be concluded that mutations in γ2 seem to interfere with the normal 
activation of AMPK by AMP 
175,179,186,190,194. Consistent with these findings, Scott et 
al reported that such mutations in the γ subunit cause a significant decrease in AMP 
binding to AMPK 
16. Abnormal regulation of AMPK could result in an imbalance in 
glucose uptake and glycogen synthesis which could explain the increased glycogen 
content in myocytes associated with this syndrome 
129.  
 
The excess storage of glycogen in the heart appears to create an insulating layer 
which causes abnormal electrical conductance characterized by ventricular 
premature excitation (abnormal activation of the ventricles by-passing the 
atrio-ventricular node) and an unexplained mild-to-severe cardiac hypertrophy. 
These traits are referred as WPW syndrome 
190,194. Patients with cardiac hypertrophy 
have an unusual electrocardiogram pattern and might be asymptomatic or experience 
chest pain, shortness of breath, congestive heart failure, syncope, and malignant 
ventricular arrhythmia. WPW is associated with an increased risk of sudden fatal 
arrhythmias in midlife and has an autosomal dominant inheritance 
175,179. 
 
Numerous groups have investigated whether the glycogen that accumulates in WPW 
syndrome is available as an energy source. Studies have shown that PRKAG2 
transgenic mice, either mutant or wild type, can utilize their stored glycogen in 
cardiomyocytes for energy production during exercise 
195. Likewise, enhanced 
glycogen storage in myocytes in Arg70Gln γ1 transgenic mice helped improving 
exercise tolerance 
188. These results indicate that therapeutic approaches to decrease 
glycogen accumulation in these patients may help to treat the disease 
194. 
 
As mentioned in section 1.1.1, conserved pairs of CBS motifs occur in metabolic 
enzymes, kinases, and channels 
16,21. Several human diseases are associated with 
point mutants in CBS motifs from these proteins. Mutations in the Bateman domains 
from cystathionine β-synthase and IMP dehydrogenase-1 result in homocystinuria 
and retinitis pigmentosa, respectively 
196-197. Additionally, mutations in the chloride   42
channels CLC1, CLC2, CLC5, CLC7 and CLCKB causes congenital myotonia, 
idiopathic generalized epilepsy, Dent’s disease, Albers-Schonberg disease and 
Bartter syndrome, respectively 
198-202. 
 
An important question is how AMP binding to CBS motifs affects the regulation of 
these enzymes and in particular of AMPK. Understanding the molecular basis of 
AMP binding to wild type and WPW mutant proteins will likely help us to 
understand the phenotypes associated with this syndrome and perhaps new ways of 
treating them. 
 
 
1.2 Project aim 
The main objective of this thesis was to characterize the mechanisms by which 
AMPK is regulated by AMP. 
 
In chapter 3 I describe the crystal structures of a regulatory fragment of AMPK in 
complex with the activator ZMP (a mimic of AMP) and with mant-AMP 
(fluorescent reporter used for my binding studies). Additionally, I report the crystal 
structures of three common WPW syndrome mutants (Arg69ÆGln, His150ÆArg 
and Arg298ÆGly) and their complexes with nucleotides. 
 
In Chapter 4 I present fluorescent binding studies aimed at determining the affinities 
of natural nucleotides, fluorescent reporters and activators for the two exchangeable 
sites of AMPK. The affinities of AXPs were also tested in the three WPW mutants 
of AMPK. HPLC studies were carried out on WPW mutants to see if the 
non-exchangeable AMP site was affected by these mutations. I also present thermal 
denaturation studies carried out on AMPK to screen a panel of putative binding 
partners that could be used for activity studies. 
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MATERIALS & METHODS 
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2. Materials & Methods 
2.1 Molecular biology 
Two pET3a tri-cistronic E. Coli expression vectors were used. The vectors encoded 
full-length His-α1β2γ1 and truncated AMPK His-α1(396-550)β2(187-272)γ1 
constructs. These vectors were provided by Dr. Richard Heath. The templates were 
used to generate the wild type and mutant AMPK constructs. All DNA stocks were 
stored at -20°C. 
 
2.1.1 Materials 
pET3a tri-cistronic E. Coli expression vectors were from Novagen. The QuikChange 
Site-Directed Mutagenesis Kit was from Stratagene. All mutagenic primers were 
synthesized by Sigma genosis. PCR reactions were carried out using a Mastercycler 
personal (Eppendorf). PCR tubes were from Elkay. QIAquick PCR Purification kit 
from Qiagen. E. coli TOP10 Competent Cells AND E. coli BL21 DE3 were from 
Invitrogen. IPTG from VWR International.  
 
2.1.2 Site-directed mutagenesis 
Three site-directed mutagenesis experiments were carried out to insert single point 
mutations to the γ-subunit of AMPK. The residues that have been mutated are 
Arg-69ÆGln, His-150ÆArg and Arg-298ÆGly. These experiments were done 
using the QuikChange Site-Directed Mutagenesis Kit according to the 
manufacturer’s instructions. Constructs were generated by PCR and standard cloning 
techniques. All mutant DNA clones were thoroughly sequenced to verify correctness 
by Hammersmith Hospital. Sequences were aligned and analyzed using Chroma 
203. 
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2.1.3 Bacterial strains 
E. coli TOP10 Competent Cells were transformed for the cloning of single point 
mutations and DNA purification procedures. E. coli BL21 DE3 competent cells were 
used in the expression of all protein constructs. The DE3 contains the T7 polymerase 
gene under the control of the lacUV5 promoter. Addition of isopropyl-β-D-
thiogalactopyranoside (IPTG) induces constitutive expression of T7 polymerase 
which results in overexpression of the protein of interest. The plasmid encodes an in-
frame amino terminal six-histidine peptide (His-tag) connected to the protein by a 
spacer and a six amino acid protease recognition sequence for identification and 
cleavage by thrombin protease (CATGAGCCATCATCATCATCATCACAGC 
AGCGGCCTGGTGCCGCGCGGCTCC). The His-tag will bind metal ions such as 
Nickel and therefore allows for protein purification via Nickel affinity 
chromatography (see section 2.2.3.1).  
 
 
2.1.4 Transformations 
Transformation is the process that enables the uptake of exogenous DNA by a 
bacteria cell. The foreign DNA integrates with the altered genome of the bacteria 
and can be used to express a recombinant protein. Transformations were carried out 
by adding 1μl of 100 ng/μl DNA solution to the E. coli competent cell aliquot. The 
cells were incubated on ice for 10 min, heat-shocked at 42°C for 50 sec and quickly 
placed on ice. 250 μl SOC medium was added. Following 1 hour incubation at 37°C 
the sample was plated on LB Agar media with ampicillin antibiotic. All plates were 
incubated overnight at 37°C. 
 
2.2 Protein biochemistry 
2.2.1 Materials 
Ampicillin, B-mercaptoethanol (BME) and Imidazole were from Sigma. Complete 
EDTA-free protease inhibitor cocktail tablets from Roche, Benzonase Nuclease    46
from Novagen. Cells were incubated during protein expression in a Multitron 2 
incubator (Infors HT) and centrifuged either in a Beckman Avanti J-25 or Beckman 
J6-MC centrifuge. Cell lysis was carried out in a Branson Sonifier 450 (Branson). 
Sterile Minisart filters (Sartorius stedim biotech) were used before and after 
purification. The P1 pump was from Amersham. Nickel-affinity purification was 
performed in a 5 ml HisTrap HP column (GE Healthcare), ion-exchange purification 
either in a Mono Q or a Mono S column (Pharmacia Biotech) and Gel filtration 
purification in a 120 ml volume Superdex 200 column (Pharmacia Biotech). All 
three chromatography techniques were carried out in columns attached to an AKTA 
Prime (Amersham) with fractionation system. Human alpha thrombin (1 mg) was 
purchased from Haematologic technologies Inc at of 36 U/μl and diluted to 0.72 
U/μl before storage at -20˚C. 4X LDS sample buffer is from Invitrogen. Ppack was 
from Calbiochem. Protein was concentrated down in Vivaspin membranes 
(Vivascience) via centrifugation carried out in Sorvall legend RT centrifuges 
(Sorvall). Instant Blue was from Expedeon. NuPage 4-12% Bis-Tris gel (15 well) 
and Mark12 Unstained Standard were from Invitrogen. Protein concentration was 
measured by using either a NanoDrop or a Cary 50 Bio spectrophotometer. Dynamic 
Light Scattering measurements of protein samples were made using Viscotek 802 
DLS Instrument (Viscotek). 
 
2.2.2 Protein expression 
One colony from a plate with transformed E. coli expression cells was used to start a 
bacterial culture in 250 ml of LB Luria-Bertani medium (LB). Ampicillin was 
prepared by dissolving in dH2O and was added as an antibiotic in the media. The 
final concentration of ampicillin was 100 μg/ml. Incubation was carried out 
overnight at a temperature of 37ºC and at a shaking rate of 200 rpm. These 250ml of 
culture were used to start a large scale expression of the proteins consisting of six 
flasks of 750ml Terrific Broth (TB) medium each, with ampicillin. When the optical 
density at a wavelength of 600 nm (OD600) reached 1.5 (4-5 hours), temperature was 
dropped to 25ºC and IPTG was added to induce cells to express AMPK protein from   47
pET3a vector (5 hours). The final concentration of IPTG was 1 mM. Cells were 
harvested by centrifugation at a speed of 4000 rpm for 30 min at 4ºC and the 
supernatant was discarded. The pellet was washed in 100 ml of 0.9% NaCl and 
recentrifuged with the same parameters as before. The supernatant was discarded 
again and the dry pellet was frozen at -20°C until cell lysis. 
 
2.2.3 Cell lysis 
Stored cell were thawed, kept on ice and resuspended in 250 ml of lysis buffer 
(50mM Tris-HCl, 100 mM NaCl, 20 mM Imidazole, 2 mM BME, 4 complete 
protease inhibitor tablets (EDTA-free), 1 mM MgCl2, 4 KU Benzonase Nuclease). 
The pH of the buffer depended on the isoelectric point (pI) of the protein expressed: 
for full-length AMPK buffer with pH 8.0 was used whereas pH 7.0 was used for the 
truncated version. Cells were lysed by sonication at 40% power in 30 s pulses for a 
total of 3 min. The insoluble fraction of the sonicate was removed by centrifugation 
at 20,000 rpm for 30 min at 4ºC. The supernatant containing the cleared lysate with 
the soluble protein was kept for further purification. An aliquot of the insoluble 
pellet was used for SDS-PAGE analysis (see section 3.1). 
 
 
2.2.4 Protein purification 
2.2.4.1 Nickel affinity purification 
The His-tag in the amino-terminal of AMPK has high affinity for divalent cations, 
such as Nickel, which are tightly bound to the protein purification column, whereas 
non-specific proteins are washed away. The 5 ml Nickel-column was pre-washed 
with binding buffer (50 mM Tris, 100 mM NaCl, 20 mM imidazole and 2 mM 
BME). As mentioned above (section 2.2.2), the pH of the buffer depended on the pI. 
of the protein construct. The cleared lysate was filtered (0.45 μm membrane) and 
loaded with a P1 pump onto the Nickel-column at a flow rate of 2 ml/min. 
Non-binding proteins were washed off with 100 ml binding buffer at a flow rate of   48
2 ml/min. Small aliquots of the flow-through from the loading and washing steps 
were collected and used later for SDS-PAGE analysis. The recombinant protein was 
eluted with a gradient that went from 0% to 100% Elution buffer (same as the 
binding buffer except for 200 mM imidazole) over 150 ml at the same flow rate as 
before. 2 ml fractions were collected over the elution procedure. If the SDS-PAGE 
gel showed a readily clean sample, gel filtration was carried out; otherwise an extra 
step of ion exchange purification was performed. 
 
2.2.4.2 Ion Exchange Chromatography 
Ion exchange chromatography enables the separation of different proteins according 
to differences in their charge. The pI of a protein is the pH at which the protein 
carries no net electrical charge. A mono-Q column, a strong anion exchanger, is used 
when the pH of the protein buffer is higher than the pI, or a mono-S column, a 
strong cation exchanger, is used when the opposite occurs. Therefore a 40 ml 
mono-Q column was used for the full-length AMPK construct (pI = 6.7, protein 
buffer pH 8.0) and a 40 ml mono-S column for the truncated AMPK construct (pI = 
8.0, protein buffer pH 7.0). The column was pre-washed with 100 ml buffer B 
(50 mM Tris, 1 M NaCl, 2 mM BME) and 100 ml buffer A (50 mM Tris, 100 mM 
NaCl, 2 mM BME). The protein sample was loaded in the column with a P1 pump at 
a flow-rate of 2 ml/min and the column washed with 100 ml of buffer A. The 
proteins was eluted by increasing the salt concentration of the elution buffer B with a 
gradient that went from 0% to 100% buffer B over 150 ml. 2 ml fractions were 
collected during the gradient and analyzed by SDS-PAGE. The fractions that contain 
a clean, concentrated recombinant protein were pulled together. 
 
 
2.2.4.3 His-Tag Cleavage 
A small scale His-tag cleavage by thrombin was carried out to determine optimal 
incubation time with the protease. The experiment was carried out at room 
temperature. 4 U of thrombin per mg of recombinant protein is used during   49
proteolytic incubation and AMPK concentration 1 mg/ml. Reactions at different 
time points of the small-scale incubation were stopped with 2x loading buffer, 
whereas the large scale reaction was stopped with the Ppack, a thrombin inhibitor 
204. 
 
2.2.4.4 Size Exclusion Chromatography 
Size exclusion chromatography separates molecules according to their size via a 
column containing porous beads. This technique is referred to as gel filtration (GF) 
chromatography, if an aqueous solution is used for diffusion of the sample through 
the column. Larger molecules travel faster along the column because they enter to 
fewer porous beads and thus diffuse to the bottom of the column before the small 
molecules which enter into a greater number of beads and therefore elute at a later 
stage. The gel filtration column was pre-washed with 100 ml GF buffer (50 mM 
Tris, 100 mM NaCl, 2 mM BME). The protein sample collected from the previous 
stage of purification was concentrated down via centrifugation (3000 rpm) to a 
volume below 5 ml and it was then filtered (0.2 µm membrane). The protein sample 
was then loaded to the 120 ml GF S200 column, washed (20 ml) and eluted at 
1 ml/min. 2 ml fractions were collected during elution and analyzed by SDS-PAGE. 
 
2.2.4.5 SDS-PAGE 
The different proteins from the aliquots of the insoluble pellet during bacterial cell 
lysis, the cleared lysate and aliquots resulting from various protein purification steps, 
e.g. wash and elution, were separated according to size using Sodium Dodecylsulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
205. Protein samples were heated 
to 100ºC for 5 min with 4X loading buffer before loading into the gel wells. The gel 
was run at 200 V with a current of 20 mA for 40 min. The different protein bands 
were visualized by staining with Instant Blue, a Coomassie based staining solution. 
The molecular mass of the protein bands were initially determined by comparison 
with Mark12 Unstained Standard and confirmed by mass spectrometry. 
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2.2.4.6 Determination of protein concentration  
Protein concentration was measured by UV-visible spectroscopy. The GF buffer 
which is used to store the protein was used as a blank. The concentration was then 
calculated using the Beer-Lambert equation: 
A = ε c l 
where “A” is the absorbance, “ε” is the theoretical extinction coefficient, “c” is the 
concentration in molarity (M) and “l” is the path length in cm. 
ε was calculated from the amino acid sequence of a protein via the ExPASy 
ProtParam tool software 
206 based on the amount of residues such as phenylalanine, 
tryptophan and tyrosine that absorb light at 280 nm 
207. 
 
2.2.4.7 Dynamic Light Scattering (DLS) 
If the purified protein was destined for crystallization trials, a DLS measurement 
was carried out to determine the oligomeric state and molecular size of the protein 
208-209. It has been established that monodispersity of proteins measured using DLS 
correlated well with the ability to grow crystals, in fact the more polydisperse a 
protein sample is, the less likely it is to crystallize. 30 µl protein samples at 
0.5 mg/ml were centrifuged (14000 rpm for 15 min) and 15 µl placed in the cuvette. 
10 measurements per sample were made for statistical validity. Proteins with a 
molecular weight that did not exceed 20% of the expected size and a polidispersity 
lower than of 20% were considered optimal samples and were used for crystal trials, 
otherwise the protein was used for binding studies. 
 
 
2.3 Crystallization 
2.3.1 Materials 
48- and 24-well trays were from Hampton research. MES, PEG 3350, PEG 4000 and 
MPD were from Sigma. 
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2.3.2 Co-crystallization of wild type AMPK with ZMP 
Crystals of truncated AMPK, α1 (rat; 396-550), β2(human; 187-272), γ1(rat) in 
complex with ZMP were grown by vapour diffusion technique at 18 ºC in a hanging 
drops tray of 48 wells. The volume in each well was 200 μl. ZMP was added to the 
protein at a final concentration of 2 mM. The protein concentration was 10 mg/ml. 
Drops were prepared by mixing equal volumes of AMPK-ZMP with well solution 
(100 mM MES pH 5.5, 7% PEG 3350) in a 2 μl drop.  
 
2.3.3 Wild type AMPK crystals soaks with mant-AMP 
Crystals of truncated AMPK were grown by vapour diffusion at 18 ºC in hanging 
drops. The 48-well tray contained 200 μl of reservoir solution. Drops were prepared 
by mixing 1 μl of AMPK sample (11.4 mg/ml protein) with 0.5 μl well solution 
(100 mM MES pH 6.4, 6% PEG 3350). Suitable crystals were transferred using a 
nylon loop into reservoir solution containing 0.5 mM mant-AMP and soaked 
overnight prior to freezing.  
 
2.3.4 AMPK-R298G mutant crystals 
Crystals of truncated AMPK with a single point mutation (Arg298ÆGly) were 
grown by vapour diffusion at 18 ºC in sitting drops either in complex with AMP or 
with no nucleotide. The 24-wells sitting drop tray had a volume of 500 μl of 
reservoir solution. Drops were prepared by mixing 1μl of protein sample AMPK-
AMP (9 mg/ml protein; 340 μM AMP) with 0.5 µl well solution (100 mM MES pH 
6.0, 8% PEG 3350). Crystals grown with AMP were transferred and soaked 
overnight in the same well reservoir with 2 mM of either ADP or ATP. 
 
2.3.5 AMPK-R69Q mutant crystals 
Crystals of truncated AMPK-R69Q were grown by vapour diffusion at 18 ºC in 
sitting drops either with no nucleotide or in complex with AMP. The 24-well sitting 
drop tray had a volume of 500 μl of reservoir solution. Drops were prepared by   52
mixing 1 μl of AMPK-AMP sample (8 mg/ml protein; 300 μM AMP) with 0.5 μl 
well solution (100 mM MES pH 6.0, 5% PEG 3350).  
 
2.3.6 Co-crystallization of AMPK-H150R mutant with AMP 
Crystals of truncated AMPK-H150R in complex with AMP were grown by vapour 
diffusion at 18 ºC in sitting drops. The 24-well sitting drop tray contained 500 μl of 
reservoir solution. Drops were prepared by mixing 1 μl of protein sample AMPK-
AMP (9 mg/ml protein; 340 μM AMP) with 0.5 µl well solution (13% 
2-Methyl-2,4-pentanediol (MPD), 3% PEG 4000).  
 
2.3.7 Freezing of crystals 
Crystals appeared in two days and grew to maximal size over 7 days. Crystals that 
reached a size of at least 50 μm in width (unless otherwise specified) were selected 
for X-ray exposure. They were cryo-protected in two steps to avoid crystal cracking. 
Crystals were harvested with a loop and transferred into a drop of reservoir solution 
with 10% ethylene glycol and then into a second drop with 25% ethylene glycol, 
before being plunged into liquid nitrogen. Frozen crystals were stored under liquid 
nitrogen until required. 
 
2.3.8 Data collection, processing and refinement 
Crystals were screened for diffraction in-house on a MicroMax 007HF rotating 
anode coupled to a RaxisIV
++ detector. Crystals were maintained at 100K using a 
cryostream and were exposed for 2 min at 0.5° oscillation at 1.54 Å λ in two 
orientations 90˚ apart. If these two images autoindexed normally, a full data set was 
collected by the oscillation method (0.5°/frame, 2 sec/frame, 0.97 Å λ) at the 
Diamond Synchrotron Light Source (UK). Only one crystal was used for each data 
set. X-ray diffraction data were processed using Denzo and Scalepack 
210. The 
structures were solved by molecular replacement with Amore 
211 or Phaser 
212 using 
wild type AMPK in complex with AMP as a search model (PDB entry: 2V8Q; 
213). 
Iterative cycles of refinement were done with Refmac5 interspersed with manual   53
rebuilding using Coot 
214-215 (see section 3.2.1). The geometry was verified with the 
program packages PROCHECK 
216 and with Molprobity 
217. Root mean square 
deviation (r.m.s.d.) in Cα positions was calculated with LSQMAN 
218. Molecular 
graphics were generated with the software Pymol 
219 and Grasp 
220.  
 
 
2.4 Binding studies 
A variety of different experimental approaches may be used to characterize the 
interaction of small molecule ligands with a protein: isothermal titration calorimetry 
(ITC), surface plasmon resonance (SPR), equilibrium dialysis, and several different 
spectroscopic (or optical) methods. The small amount of sample required and the 
short data collection time make the optical methods particularly useful tools in such 
studies as well as in the study of protein stability. A series of fluorescence based 
binding studies have been carried out to characterize the interaction of AMPK with 
the adenine nucleotides: AMP, ADP and ATP. For some proteins the binding of 
adenine nucleotides has been monitored though their effects on the intrinsic 
(generally tryptophan) fluorescence of the protein. However, such studies are 
generally of limited applicability because of the strong absorption of the nucleotides 
at the wavelengths used to excite intrinsic protein fluorescence 
221. An alternative 
approach is to use fluorescent analogues to monitor binding and then to use either 
competition or displacement experiments to characterize the binding of the natural 
nucleotides. In this study, N-methylanthraniloyl (mant)-nucleotides and NADPH (or 
NADH) have been used as the fluorescent reporters. 
 
2.4.1 Materials 
Mant-AMP and mant-ATP were kind gifts from Dr John Eccleston. AMP, ADP and 
ATP were all purchased from Sigma and ZMP was purchased from Calbiochem. 
Stock solutions of these nucleotides were prepared in GF buffer and stored at -20˚C. 
NADH, NADPH, NAD+ and NADP+ (Sigma) were freshly prepared each day 
because of potential stability problems 
222. Concentrations of all nucleotide stock   54
solutions were determined using published extinction coefficients. The A-769662 
compound was a gift from AstraZeneca and was dissolved in dimethyl sulfoxide 
(DMSO). The phosphopeptide was synthesized by Dr Graham Bloomberg at the 
University of Bristol and was dissolved in GF buffer. The 413 compounds used in 
the thermal binding assays were provided by the MRC Technology Division and 
were dissolved in DMSO at a final concentration of approximately 1mM.  
The Partisil 10 SAX column used in the nucleotide assays was from Whatman. 
Fluorescence measurements were made using two spectrofluorimeters: an ISS 
photon counting instrument and a Jasco FP 6300. Thermal unfolding assays were 
carried out using a temperature-controlled Jasco V-550 UV/Vis spectrophotometer. 
The 3 mm and 5mm light path cuvettes used for fluorescence spectroscopy and the 
micro-cuvette with a 10 mm path-length used for thermal denaturation experiments 
were from Hellma 
 
Ligand binding to AMPK was tested using the full-length protein (phosphorylated 
and non-phosphorylated forms), and a truncated AMPK α1(396-548)β2(187-272)γ1 
construct. Protein concentrations were routinely determined using calculated 
extinction coefficients (117580 M
-1cm
-1 at 280 nm for the full length protein and 
59250 M
-1cm
-1 at 280 nm for the truncated construct). 
 
 
2.4.2 Fluorescent binding studies 
Uncorrected fluorescence emission spectra of the N-methylanthraniloyl 
(mant)-nucleotides and their complexes with AMPK were recorded at 20ºC (unless 
otherwise specified) with an excitation wavelength of 380 nm (bandwidth 2.5 nm) 
and emission scanned from 400 to 550 nm (bandwidth 10 nm). The free 
(uncomplexed) mant-nucleotides have an emission maximum at 446 nm. In the 
presence of saturating AMPK the emission maximum is blue-shifted to 
approximately 430 nm and the fluorescence intensity is increased up to 5-fold. 
Binding of mant-AMP was generally monitored by adding AMPK to a solution of 
the nucleotide in a buffer containing 25mM Tris-HCl (pH depending on the pI of the   55
construct used) and 100 mM NaCl. Due to the unstable nature of AMPK, following 
each titration the sample was mixed not by stirring but by gently pipetting in and out 
the solution. Some experiments were also performed at low temperature and/or in 
the absence of salt (conditions expected to strengthen binding of the nucleotide) in 
order to establish the stoichiometry of the interaction. Competition assays in the 
presence of 50 µM AMP, ADP or ATP were used to determine the Kd values for the 
adenine nucleotides. The binding of A-769662 and ZMP to AMPK were assessed 
using a similar approach. 
 
For the mant-nucleotides it is possible to use a different, but complementary, 
approach in which binding is monitored by adding the nucleotide to a solution of 
AMPK in ISS buffer (25mM Tris-HCl [pH depending on the pI of the construct 
used], 100 mM NaCl), rather than by adding the AMPK to the nucleotide. In this 
case the excitation wavelength used is 290 nm rather than 380 nm. At this shorter 
wavelength there is relatively little direct excitation of the mant fluorophore but 
significant excitation of the tryptophan residues in AMPK. The signal monitored in 
this experiment is the mant fluorescence (400-550 nm) which arises through Förster 
resonance energy transfer (FRET) from AMPK’s tryptophan(s) to the mant group. 
Electronic excitation energy can be transferred by this dipole-dipole resonance 
interaction between donor and acceptor fluorophores over distances that extend to 
30 Å and more 
223 and several groups have used this FRET based approach to study 
protein-ligand interactions 
221,224-225.  
 
Fluorescence emission spectra of the reduced forms of β-nicotinamide adenine 
dinucleotide (NADH) and β-nicotinamide adenine dinucleotide 2’-phosphate 
(NADPH) and their complexes with AMPK were recorded with an excitation 
wavelength of 340 nm (bandwidth 2.5 nm) and emission scanned from 400 to 550 
nm (bandwidth 10 nm). Free (uncomplexed) NADPH has an emission maximum at 
461 nm. In the presence of saturating AMPK the fluorescence intensity is increased 
by 4-10 fold (depending on the AMPK construct used) and the emission maximum 
is blue-shifted to approximately 428 nm. Binding of NADPH was monitored by   56
adding AMPK to a 10 µM solution of the nucleotide in ISS buffer (25mM Tris-HCl 
[pH depending on the pI of the construct used], 100 mM NaCl). Some experiments 
were also performed at low temperature and/or in the absence of salt (conditions 
expected strengthen binding) in order to establish the stoichiometry of the 
interaction. Competition assays in the presence of either 12.5 µM or 25 µM AMP, 
ADP or ATP were used to determine the Kd values for the adenine nucleotides. 
Competition assays in the presence of NAD
+ or NADP
+ were done with either 250 
µM or 500 µM nucleotide concentrations. The binding of ZMP to AMPK was 
assessed using a similar approach. FRET based measurements with NADPH could 
not be performed because excitation at 290 nm would produce far too much direct 
excitation of NADPH.  
 
2.4.3 Bound nucleotide analysis 
Solutions of AMPK at known concentration were denatured with perchloric acid and 
sodium acetate and then centrifuged to remove the protein. The supernatant was 
applied to Partisil 10 SAX (strong anion-exchange) column and eluted with 0.6M 
NH4H2PO4 at 1 ml/min with absorbance monitoring at 260 nm. The concentrations 
of the different nucleotides present in the protein sample were estimated by 
integrating peaks and comparing the areas with those produced by nucleotide 
standards with known concentration. 
 
 
 
2.4.4 Thermal stability measurements 
The stability of a protein can be assessed by monitoring any of several optical 
signals (e.g. circular dichroism) that change when the protein unfolds at high 
temperature. If a ligand binds only to the folded form of the protein then it will 
increases its stability and unfolding will occur at a higher temperature. Such studies 
have become an increasingly important tool in the search for new drugs 
226-227. The 
AMPK construct used here was the trimeric complex α1(396-550)β2(187-272) with   57
full-length γ1. Protein samples were prepared in GF buffer (50 mM Tris-HCl pH 7.0, 
100mM NaCl) at a concentration of 1.5 µM and then heated at 1 degree/minute from 
40 to 70˚C in a UV/Vis spectrophotometer. It is important to note that what is being 
monitored here (absorbance at 400 nm) is the turbidity increase associated with 
protein aggregation. Despite the irreversible nature of protein unfolding for many 
large proteins, it has been suggested that irreversible unfolding may be treated as 
two discrete steps; where a relatively fast folded to unfolded reaction is uncoupled 
from a much slower aggregation step. Under this condition, an apparently 
irreversible process may be treated as a reversible unfolding transition 
227. 
Determination of the mid-point for unfolding was performed using in-house 
software written by Dr Stephen Martin (Division of Physical Biochemistry, NIMR). 
 
2.4.5 Statistics 
Unless otherwise specified, experiments shown are representative of two or three 
studies that gave similar results. Results of averaged experiments are given as means 
± SD. 
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3. Results - crystallography 
3.1 Protein purification 
AMPK was overexpressed in E. coli. The bacterial cells were harvested by 
centrifugation, lysed by sonification, and the soluble lysate was loaded onto a 
Nickel-affinity column (section 2.2.1). The column was washed with an imidazole 
gradient from 20 mM to 200 mM and the protein eluted at approximately 100 mM 
imidazole. Fractions containing AMPK were analyzed by SDS-PAGE and then 
appropriately pooled (section 2.2.3.1) (Fig 3.1A). Samples of the pellet, lysate, 
flow-through and wash were also analyzed. 
 
The pooled fractions were loaded onto an ion exchange chromatography column. 
Proteins were eluted by increasing the salt concentration from 100 mM to 1 M NaCl 
(section 2.2.3.2). AMPK eluted at approximately 250 mM NaCl. SDS-PAGE 
analysis of various fractions are shown in Figure 3.1B. 
 
The N-terminal His-tag was removed from recombinant AMPK by proteolytic 
cleavage with thrombin. In order to determine the minimum amount of thrombin 
needed to cleave the His-tag, without beginning to cleave the protein at other sites, a 
pilot scale (80 μl) thrombin cleavage experiment was done. Different time points 
were taken (0, 1, 2, 5, 10, 30 min) and subsequently analyzed by SDS-PAGE (Fig 
3.1C). The optimal time length of incubation of AMPK with thrombin was then used 
for the large-scale prep and the reaction was stopped with Ppack, a potent small 
molecule thrombin inhibitor 
204. The un-tagged AMPK was separated from the 
His-tag, Ppack and Thrombin in the subsequent gel filtration step. 
 
The protein was concentrated by centrifugation using Vivaspin concentrators 
(3000 rpm) to approximately 5 ml and loaded onto a S200 size exclusion column. 
The buffer used to elute the protein is the same as used to store the protein after 
purification (Fig 3.1D). The yield of purified protein from one litre of culture was 
approximately 5 mg.   60
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Figure 3.1: SDS-PAGE analysis of (A) Nickel purification, (B) ion exchange, (C) 
small scale thrombin incubation and (D) Gel filtration of the truncated construct of 
AMPK. The molecular weight of α, β and γ subunits are 19, 10 and 37 kDa. In C, the 
time points taken were 0, 1, 2, 5, 10, and 30 min. M, marker; P, pellet; L, lysate; FT, 
flow-through; W, wash. Arrows indicate the position of cleaved and uncleaved α 
subunit from the His-tag. 
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3.2 Crystallography 
3.2.1 Overview 
In this thesis I describe the structure of a number of different complexes of either 
wild type or mutant AMPK. The wild-type is in complex with the activator ZMP, an 
intermediate on the biosynthetic route to AMP, or with mant-AMP, the fluorescent 
reporter used in binding studies (see section 3.4.3). In addition, I present the crystal 
structures of three AMPK mutants which carry single point mutations in the γ 
subunit responsible for Wolff-Parkinson-White syndrome: Arg-69ÆGln (R69Q), 
His-150ÆArg (H150R) and Arg-298ÆGly (R298G). The structures of the mutants 
reveal that nucleotide binding is impaired in one of the two exchangeable sites, 
which might explain the dysregulation of the kinase in patients with WPW disease. 
 
 
Since initial crystallization trials using full-length mammalian AMPK were 
unsuccessful, a truncated protein was designed from the results of limited proteolysis 
and sequence analysis. The construct used contains the carboxyl terminus of α1 (rat; 
396-550) and β2 (human; 187-272) with full-length γ1 (rat) (Fig 3.2A). The protein 
was co-crystallized with AMP, although further soaking experiments with ADP, 
Mg
2+-free ATP and Mg
2+-ATP also took place. Crystals of this protein construct 
commonly grow in a tetragonal habit (Fig 3.2B) but belong to the orthorhombic 
space group P212121. The diffraction limit of the different protein crystals ranges 
from 2.0 Å to 2.6 Å Bragg spacing. Diffraction data were processed using Denzo 
and Scalepack 
210. The structures were solved by molecular replacement using 
Amore  or Phaser 
211-212. The starting phases for the calculation of initial electron 
density map were obtained from the model of wild type AMPK in complex with 
AMP which was solved in our lab and was refined at 2.1 Å resolution (PDB entry: 
2V8Q) 
213. All three nucleotides, as well as water molecules, were omitted from the 
molecular replacement and phase calculations. Crystallographic refinement was 
carried out using the rigid body, simulated annealing and TLS protocol of the   62
program package Phenix 
228. After each round of refinement, the models were 
manually adjusted using the computer graphics program Coot where necessary 
215. 
In cases where the electron density for some residues or segments was ambiguous 
the following procedure was followed. Selected residues were given zero occupancy 
in the coordinate files prior to some cycles of refinement, the resulting phases were 
then used calculate less biased electron density maps which were often useful in 
identifying the correct build. Water molecules were initially incorporated by Coot 
and then manually added into remaining positive electron density peaks. Water 
molecules closer than 2.2 Å to each other or 2.5 Å from nitrogen and oxygen or 
3.5 Å from carbons atoms of the protein complex were removed. B-factor values 
were refined but atom occupancies were left at 1.0 during refinement. Other rounds 
of refinement were carried out using the program package Refmac5 
214. Temperature 
factor refinement and manual adjustment of side-chains and solvent positions were 
carried on until the RFree did not decrease any further and no interpretable features 
were left in the difference electron density maps.  
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Figure 3.2: (A) Diagrammatic representation of the three subunits of the 
heterotrimer. The construct used for crystallography is outlined in red. (B) Typical 
crystals of truncated AMPK which grow in a tetragonal shape. 
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3.2.2 Overall structure 
The inter-subunit interactions between the three subunits are primarily mediated by 
the last two anti-parallel strands of the beta subunit (β 249-272, colored in green) 
with a strand from the N-terminal of the gamma subunit (γ 42-76, colored in red) 
and a loop at the C-terminus of the alpha subunit (α 530-544, colored in cyan) (Fig 
3.3A). The gamma subunit is disk-shaped and approximately 60 Å in diameter and 
with a thickness of 30 Å. The γ subunit is made up of four CBS motifs arranged as 
two Bateman domains 
16-17. As observed in several crystal structures of CBS motifs, 
in our truncated AMPK structure, each one of the four CBS motifs consists of a 
conserved α1-β2-β3-α4 pattern in an anti-parallel arrangement 
21 (Fig 3.3B). Each 
pair of CBS domains is associated via hydrophobic interactions between 
homologous β sheets, making it unlikely that single domains would be stable in 
solution (Fig 3.3B). The packing of these four pseudo-symmetric motifs generates 
four potential adenyl binding sites. The truncated wild type structure of AMPK was 
first solved as a complex with AMP, then crystals were soaked in ATP. The 
structure shows how one nucleotide binds between CBS 1-2 (site-1) and two 
nucleotides between CBS 3-4 (site-2 and site-3) (Fig 3.3B). Between CBS 1-2 there 
is a potential fourth nucleotide binding site, but thus far no nucleotide has been seen 
to bind at this site; this issue will be discussed in more detail in section 5.6. Each of 
the three nucleotides sits in a partially basic pocket formed at the interface between a 
pair of CBS domains (Fig 3.3C&D). Interestingly, binding site-3 does not undergo 
nucleotide exchange and seems to exclusively bind an AMP molecule which has 
been shown to co-purify with the protein (see section 3.3) 
213. The other two 
nucleotide binding sites can exchange between AMP, ADP or ATP.  
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Figure 3.3: Ribbons (A&B) and surface (C&D) representation of AMPK in complex 
with three AMP molecules. In (A, B & C) the same view is shown. The three 
subunits in (A) are colored according to Fig 3.2A. Bateman 1 is shown in more 
detail in (B). CBS 1-2 (Bateman 1) are colored in blue and yellow, whereas CBS 3-4 
(Bateman 2) are in orange and magenta, respectively. (C) Front view with site-1 and 
site-3; (D) Reverse view showing site-2. The surface is colored according to the 
electrostatic potential [blue, positive (contour level +30.0 KbT / ec); red, negative 
(-30.0 KbT / ec)]. AMP molecules are in stick representation with carbon atoms in 
yellow. 
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One of the key features of the binding site is the hydrogen bonding of the two 
hydroxyl groups of the ribose with the side chain of an aspartate residue (Asp 89 
with site-1, Asp 244 with site-2 and Asp 316 with site-3) (Fig 3.4A). 
 
 
Figure 3.4: (A) Typical interaction between an AMP molecule and residues from 
the γ subunit. The binding site represented here is site-1. (B) Additional interaction 
between ATP and side chains of the protein (Lys 242 with ATP-1 and Arg 151 with 
ATP-2). The three phosphates of ATP are labelled in red. The AMP & ATP 
molecules are in stick representation with carbon atoms in yellow, the protein is in 
blue with the carbon atoms of residues that hydrogen bond with the nucleotide in 
green.   
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On the adenosine moiety, the amino group at N6 acts as a hydrogen bond donor to 
two main chain carbonyl groups from the enzyme (Val-129 and Arg-151 in site-1; 
Leu-276 and Arg-298 in site-2; Ala-204 and Ala-226 in site-3) (Fig 3.4A). The N1 
atom hydrogen bonds with the amino group from the main chain of AMPK 
(Val-129, Leu-276 and Ala-204 with site-1, site-2 and site-3, respectively) (Fig 
3.4A). The phosphate groups interact with the hydroxyl groups of serine or threonine 
residues (Thr-86 and Thr-88 in site-1; Ser-241 in site-2; Ser-225, Ser-313 and 
Ser-315 in site-3) and with the positively charged side chains of a number of 
different residues (His-150 and Arg-151 in site-1; Arg-69, Lys-169, Arg-298 and 
His-297 in site-2; His-150 and His-297 in site-3). Turning to the ATP complex, the γ 
phosphate of ATP makes an extra interaction with Lys-242 in site-1 and with 
Arg-151 in site-2, which is not possible when either AMP or ADP is bound (Fig 
3.4B). 
Hydrophobic interactions also contribute significantly to nucleotide binding, 
including the interactions from the carbon atoms of the adenosine moiety with 
Met-84 and Leu-128 (in site-1), Ile-236, Val-275 and Val-296 (site-2) and Ile-203 
and Val-224 (site-3) (Fig 3.4A).  
 
Although the nucleotides bind at the interface of two CBS motifs that make up a 
Bateman domain, there are some interactions of the nucleotides with amino acids 
from the “other” Bateman domain; for example AMP-2 interacts with residues 
predominantly from CBS3-4, but also with Arg-69 and Lys-169 (which belong to 
CBS-1 and -2, respectively); AMP-3 interacts with residues from CBS3-4 but also 
with His150 (CBS-2) (Fig 3.5).  
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Figure 3.5: Ribbons representation of AMPK in complex with three AMP 
molecules. CBS 1-2 (Bateman 1) are colored in red and orange, whereas CBS 3-4 
(Bateman 2) are in yellow and magenta, respectively. AMP molecules are in stick 
representation with carbon atoms in green. 
 
There are disordered loops in both the α- and β-subunits: α-470 to α-523 and β-223 
to β-232. Two loops in the γ subunit that are close to the two exchangeable AXP 
binding sites also show relatively poor electron density; γ-120 to γ-128 and γ-265 to 
γ-278 being adjacent to site-1 and -2, respectively. 
 
 
3.2.3 Wild type AMPK structure in complex with ZMP 
To study the binding of ZMP, an AMP mimic that has been investigated as a 
potential therapeutic agent, I carried out a series co-crystallization experiments of 
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AMPK with ZMP. Crystals were initially obtained with a protein concentration of 
10 mg/ml and 2mM ZMP. The precipitant used contained MES, isopropanol and 
glycyl-glycyl-glycine and crystals grew up to 35 μm in width, and diffracted to 
about 2.9 Å. (Table 3.1). The merging statistics of the data were relatively poor 
(Rmerge in the resolution shell between 3.0 Å and 2.9 Å was 0.32). Data merging and 
refinement statistics are given in Table 3.1. The relatively poor quality of this data is 
evident from these statistics. 
 
 
Table 3.1: Crystallographic statistics of the AMPK/ZMP complex. The highest 
resolution shell is shown in parenthesis. 
 
 
 
 
Data collection 
 
   Refinement 
 
 
method Co-crystallization  No. relections  17035 
Space group  P212121   No. atoms: Protein 
                  Ligand 
                  Water 
3896 
45 
66 
Cell dimension: a, b, c (Å) 
                           α, β, γ (˚) 
48.3 123.8 124.4 
90, 90, 90 
 R Work/RFree (%)  24.2/32.4 
 
Resolution (Å) 
 
30-2.9 (3.0-2.9)
 B-factors  (Å
2): Protein 
                       ZMP-1 
                       ZMP-2 
                       AMP-3 
                       Water 
41.4 
38.8 
no 
32.5 
43.0 
Rmerge  11.2 (32.0)    R.m.s deviations from standard geometry:  
I/σ  9.3 (1.4)    Bond length (Å)  0.015 
Completeness (%)  95.3 (87.9)    Bond angles (˚) 1.738 
Redundancy 
 
 
3.0 (2.5)         70
Although there was some electron density for three nucleotides in the binding sites, 
the structures of AMP and ZMP are too similar to adequately differentiate at this 
resolution (Fig 3.6). Therefore further crystallization trials using 100 mM MES pH 
5.5 and 7% PEG 3350 as a precipitant were undertaken that resulted in the growth of 
larger crystals (55 μm). These crystals diffracted to higher resolution and were 
processed to 2.1 Å. Crystallographic statistics are shown in Table 3.2.  
 
       
 
Figure 3.6: Structures of AMP (left) and ZMP (right). The only differences appear 
in the base moiety: AMP has an adenosine whereas ZMP has an imidazole group.  
 
 
 
 
 
 
 
 
 
O 
NH2   71
 
Table 3.2: Crystallographic statistics of the AMPK/ZMP complex using a crystal 
grown in MES, and PEG 3350. The highest resolution shell is shown in parenthesis. 
 
 
 
 
The structure was solved by molecular replacement. The Rfactor of the initial model 
was 33.4 %. Following refinement the final Rwork and RFree were 23.9 % and 27.1 %. 
The average protein B factor is 42.8 Å
2, and the B factor for the ZMPs in site-1 and 
site-2 and AMP-3 are 40.9, 55.2 and 36.5 Å
2, respectively. The geometry of the 
model is within the normal range for refined structures. The root mean square 
deviations (r.m.s.d.) from standard geometry is 0.008 Å for bond length and 1.6º for 
Data collection     Refinement 
 
 
Method Co-crystallization  No.  unique relections  44170 
Space group  P212121    No, atoms: Protein 
                  Ligand 
                  Water 
3881 
67 
203 
Cell dimension: a, b, c (Å) 
                           α, β, γ (˚) 
48.6, 124.7, 124
90, 90, 90 
  RWork/RFree (%)  23.9/27.1 
 
Resolution (Å)  
 
 
Rmerge 
 
30-2.1 
(2.20-2.10) 
 
7.1 (53.1) 
 B-factors  (Å
2): Protein 
                       ZMP-1 
                       ZMP-2 
                       AMP-3 
                       Water 
42.8 
40.9 
55.2 
36.5 
37.9 
     R.m.s deviations from standard geometry: 
I/σ  19 (3.2)    Bond length (Å) 0.008 
      Bond angles (˚) 1.589 
Completeness (%)  98.7 (98.5)    Ramachandran plot (%):    
     favored 94.9 
Redundancy 
 
 
5.1 (5.2)    outliers 0.8   72
bond angles. Analysis of the final Ramachandran plot revealed that more than 
94.9 % of the residues adopted the most favorable conformational angles whereas 
less than 0.8 % lie in additional disallowed regions.  
 
Good quality electron density for two ZMP molecules in the exchangeable 
nucleotide sites (site-1 and site-2) was evident from the initial difference (Fobs - Fcalc) 
map (Fig 3.7A&B). Site-3 is again occupied by an AMP molecule (Fig 3.7C). The 
ZMP I built into the site previously referred to as AMP-1 I will refer to as ZMP-1 
and likewise for AMP-2/ZMP-2. The non-exchangeable AMP-3 site retains its 
nomenclature. The structures of AMPK/AXP and AMPK/ZMP complexes are very 
similar over the α- and β-subunits (with a root mean square (r.m.s.) deviation of 0.26 
and 0.65 Å respectively). In contrast, the γ-subunit shows differences in the 
conformation of some loops associated with the two exchangeable nucleotide-
binding sites (Fig 3.7D). The loops close to site-1 (residues γ-121 to γ-127) and 
site-2 (residues γ-268 to γ-275), seem to be in a more closed conformation when 
ZMP binds respect to when AXPs bind. The biggest shift involves phenylalanine 
residue γ-125 in site-1 and γ-272 in site-2 which move 6.8 and 3.9 Å respectively. 
The environment of the binding site containing the non-exchangeable AMP-3 sits 
remains unchanged.  
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Figure 3.7: Structure of AMPK/ZMP complex: Electron density maps surrounding 
the exchangeable binding pocket site-1 before [A, (Fobs - Fcalc)] and after [B, 
(2Fobs - Fcalc) modeling in a ZMP molecule. The (Fobs - Fcalc) map is contoured at 
2.5 σ for ZMP-1 (A) and AMP-3 (C) whereas the (2Fobs - Fcalc) is at 1.5 σ (B); the 
electron density has been selected on the basis of being 1.6 Å from the coordinates 
of the ligand. (D) Superposition of the γ subunit from the AMPK/AMP (green) and 
AMPK/ZMP (red) complexes (left, site-1; right, site-2). ZMP and AMP molecules 
are represented with carbon atoms in yellow and green sticks, respectively. 
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Overlap of the AMPK/ZMP and the AMPK/AXP complexes reveals that the ZMPs 
and AMPs do not superpose exactly (Fig 3.8A). The phosphate groups of the three 
nucleotides shows some differences, between AMP and ZMP, interacting with basic 
residues of the protein; the interaction between Arg-69 and Lys-169 with ZMP-2 is 
lost due to a rearrangement of the side chains of these two residues. Interestingly, the 
imidazole group of His-297 is rotated about 120˚ away from AMP-3, and in its new 
rotamer conformation, His-297 interacts with the phosphate from ZMP-2. Due to the 
slight shift of the ZMP molecule in the pocket, the new rotamer of His-297 does not 
clash with the phosphate group of AMP-2 as seen in the WPW mutant AMPK 
described later (section 3.2.5). Otherwise the residues that interact with ZMP are 
largely the same as with the AMPK/AXP complex, although there are some changes 
in bond lengths (Fig 3.8B). The interaction between the adenosine part in the 
AMPK/ZMP complex involves two hydrogen bonds between the amino group at 
position 2 (equivalent to N6 of AMP) with the carbonyl group of the main chain of 
Val-129 and Arg-151 in site-1 and Leu-276 and Arg-298 in site-2. The O5 atom of 
ZMP (corresponding to N1 of AMP) hydrogen bonds with the main chain amide of 
the enzyme (Val-129 and Leu-276 in site-1 and site-2, respectively) (Fig 3.8B). The 
two loops close to the exchangeable binding sites contain residues that are outliers in 
the Ramachandran plot: Ser-124 and Lys-126 close to site-1 and His-270, Tyr-271 
and Val-275 in the loop close to site-2. Residues Thr-253 and Tyr-254 have been 
deleted from the model as the electron density is unclear, and the use of an omit map 
did not help in building them. 
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Figure 3.8: (A) Overlap of AMP-2 from the AMPK/AXP complex with ZMP-2 
from the AMPK/ZMP. (B) Hydrogen bonding between the base of ZMP-1 (left) and 
AMP-1 (right) with main chain atoms of Val 129 and Arg 151. ZMP and AMP 
molecules are represented with carbon atoms in yellow and green sticks, 
respectively. 
 
A free 6-NH2 group in the nucleobase in AMP may be critical for ligand binding to 
the nucleotide binding sites and the structure of AMPK with ZMP shows the same 
interactions with the protein explaining why ZMP, and not other nucleotides in the 
cell other than AMP, bind and activate AMPK (discussed in detail in section 4.2; 
Fig 3.8B). The loss of interaction betweens basic residues and ZMP probably 
explain the reduced affinity of this compound for AMPK (detailed fluorescent 
binding studies are in section 3.4.7), and hence the reduced potency of this drug for 
AMPK compared to AMP. 
A 
Val 129 
Arg 151 
B 
N2 
O5 
N6 
N1  Val 129 
Arg 151   76
 
3.2.4 Wild type AMPK structure in complex with mant-AMP 
To confirm that the fluorescent reporters used for later binding studies (see section 
4.2) are binding in a similar and thus competitive manner with unlabelled AMP, I 
carried out a series of soaking experiments of AMPK with mant-AMP. Crystals 
obtained from 11.4 mg/ml protein with 100 mM MES pH 6.4 and 6% PEG 3350 
were soaked overnight with 0.5 mM mant-AMP. The soaked crystal diffracted to 
2.1 Å and the crystallographic statistics for data collection and refinement are given 
in Table 3.3.  
 
 
Table 3.3: Crystallographic statistics for the AMPK/mant-AMP complex. The 
highest resolution shell is shown in parenthesis. 
 
Data collection     Refinement 
 
 
Method Soaking    No.  unique relections  44456 
Space group  P212121   No. atoms: Protein 
                  Ligand 
                  Water 
3804 
89 
241 
Cell dimension: a, b, c (Å) 
                           α, β, γ (˚) 
49, 123.6, 124.9
90, 90, 90 
  RWork/RFree (%)  23.0/26.3 
Resolution (Å)  30-2.1 
(2.20-2.10) 
 B-factors  (Å
2): Protein 
                       mAMP-1 
                       mAMP-2 
                       AMP-3 
                       Water 
43.4 
48.6 
67.9 
36.5 
41.0 
Rmerge 6.2  (42.9)    R.m.s deviations from standard geometry: 
I/σ  16 (2.1)    Bond length (Å)  0.008 
Completeness (%)  99.5 (100)    Bond angles (˚) 1.321 
Redundancy  3.7 (3.7)    Ramachandran plot (%):    
     favored 97.4 
     outliers 0.2   77
 
The structure was solved by molecular replacement as before using 2V8Q as a 
model. The starting Rfactor was 30.9%. Following refinement the final RWORK and 
RFREE were 23.0 and 26.3%, respectively. The average protein B factor is 43.4 Å
2, 
and the B factor for mant-AMP-1, mant-AMP-2 and AMP-3 are 48.6, 67.9 and 
36.5 Å
2, respectively. The geometry of the model is within the normal range for 
refined structures. The r.m.s. deviation from standard geometry is 0.008 Å in bond 
length and 1.3º in bond angles. Analysis of the final Ramachandran plot revealed 
that greater than 97.4 % of the residues adopt the most favorable conformational 
angles and just 1 residue, Thr-253 lies in the additional disallowed regions.  
 
 
 
The electron density for the mant-AMP in site-1 and site-2 was clear from the first 
map with strong positive (Fobs – Fcalc) electron density for the AMP and mant 
moieties (Fig 3.9A). The mant-nucleotides were built into the electron density maps 
and subsequently refined as part of the atomic model. As expected, site-3 showed 
electron density for AMP.  
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Figure 3.9: (A) Electron density of the initial difference map (Fobs - Fcalc) contoured 
at 2.5 σ is on the left. A portion of the electron density map (2Fobs - Fcalc) after 
mant-AMP had been refined in the atomic model is contoured at 1.0 σ, right. (B) 
Atomic model of mant moiety with numbered positions. The binding pocket shown 
is site-1. Carbon atoms of the mant-AMP are in yellow sticks.  
 
Asp 89 
Asp 89 
A 
B 
C6B 
Asn 92 
Tyr 120 
Leu 121 
Gln 122 
Lys 126 
O1B 
CM 
C4B  C5B 
C1B 
C3B 
O3’  O2’   79
 
The monophosphate and the adenyl parts of the mant-nucleotide adopt similar 
conformations to those observed in the AMP complex with AMPK. The structure of 
mant-nucleotide consists of an AXP molecule with a mant group linked to the ribose 
at the 3’ position (Fig 3.9B). The usual bi-dentate interaction that is formed between 
the 2’ and 3’ hydroxyl groups of the ribose with an aspartic acid can not be formed 
in the presence of the mant substituent. Instead, the side chain of the aspartate makes 
a single hydrogen bond interaction with the 2’-OH.  
 
There are limited contacts between the fluorescent mant group and the protein and it 
does not seem to cause any changes to the structure of the protein. The mant group 
from the nucleotide in site-1 hydrogen bonds with Asn-92 through the carbonyl 
oxygen labelled O1B in Fig 3.9A. Hydrophobic interactions between the mant 
moiety and the protein include the methylamine group interacting with the aromatic  
ring of the side chain of Tyr-120, atom C4B with the side chain of Leu-121, atom 
C5B with the Cβ of Gln-122 and C6B with the alkyl part of the side chain of 
Lys-126 (Fig 3.9B). In site-2, the carbonyl in the mant moiety does not hydrogen 
bond with the protein, but hydrophobic interactions stabilize the binding of the mant 
moiety in a similar manner to site-1: the methylamine makes hydrophobic contact 
with the Cγ of Arg-268 and the carboxyl group from the main chain of Tyr-271. 
Atom C2B makes hydrophobic contact with the side chain of His-270, C3B with the 
amino group of the main chain of Ser-269, C4B with Cβ from Ser-269 and atom 
C6B interacts with Phe-243. The mant group extends outside the normal binding 
pocket and therefore does not alter the binding of the adenyl moiety (Fig 3.10). 
Interestingly, the loops close to the two exchangeable binding sites that are usually 
poorly defined are, in this case, well ordered enabling them to be built into the 
atomic model.    80
 
Figure 3.10: Surface representation of AMPK in complex with mant-AMP. The 
pocket shown is site-1. The surface is colored according to the electrostatic potential 
[blue, positive (contour level +30.0 KbT / ec); red, negative (-30.0 KbT / ec)]. 
Mant-AMP is in stick representation with carbon atoms in yellow. 
 
Detailed fluorescence binding studies using mant-AMP are described in section 
4.2.3. The binding data suggests a stoichiometry of 2:1 (mant-AMP/AMPK). The 
crystal structure of the regulatory subunit of AMPK in complex with mant-AMP 
presented here confirms that the binding of the fluorescence reporter is specific, i.e. 
two molecules of mant-AMP bind to the exchangeable nucleotide binding sites and 
that this reporter binds competitively with the unlabelled nucleotide, whereas site-3 
remains non-exchangeable. 
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3.2.5 Structures of Wolff-Parkinson-White (WPW) mutants 
To gain insight into the mechanism of WPW mutations of AMPK, I undertook a 
series of crystallization experiments to determine the structures of Arg69ÆGln, 
His150ÆArg and Arg298ÆGly –three of the naturally occurring mutants that cause 
WPW. Protein crystals grew in sitting and hanging drops by vapour diffusion with a 
protein concentration ranging from 8 mg/ml (for His150ÆArg and Arg298ÆGly) to 
9 mg/ml (for Arg69ÆGln). Arg69ÆGln crystals grew in 100 mM MES, pH 6.0 and 
5% PEG 3350 to a width of 120 μm. Arg298ÆGly crystals grew in 100 mM MES, 
pH 6.0 and 8% PEG 3350. Apo crystals for Arg298ÆGly grew up to 200 μm in 
width but in complex with AMP were only about 90 μm (Fig 3.11). In the case of 
the His150ÆArg mutant, crystallization was problematic and after much screening 
only a precipitant containing AMP, 13 % MPD and 3 % PEG 4000 produced single 
crystals which grew to 40 μm. See section 2.3.5 for more details. I could not grow 
crystals of the apo form for the His150ÆArg mutant. For Arg69ÆGln and 
Arg298ÆGly, apo protein produced the largest crystals. My experience, not 
uncommon, was that larger crystals resulted in higher resolution diffraction (e.g. the 
200 μm apo crystal of Arg298ÆGly diffracted to 2.0 Å resolution, whereas the 
40 μm crystal of His150ÆArg to only 2.6 Å Bragg spacing. 
 
    
 
Figure 3.11: Typical crystals of WPW mutant AMPK. Apo crystals reached 200 μm 
in width (left), whereas protein in complex with AMP produced crystals of about 
90 μm (right).   82
Summary of the crystallographic statistics for the three mutants AMPKs in complex 
with AMP are listed in Table 3.4A. Arg298ÆGly is also presented in the apo form 
and in complex with ADP or ATP in Table 3.4B.  
 
Data collection  R69Q H150R  R298G 
Space group  P212121 P212121 P212121 
Cell dimension: a, b, c (Å) 
                           α, β, γ (˚) 
48.5, 119.2, 128.5 
90, 90, 90 
48.9, 124.3, 123.8 
90, 90, 90 
48.5, 121.7, 126.6
90, 90, 90 
Resolution (Å)  30-2.1 
(2.20-2.10) 
30-2.6 
(2.72-2.60) 
30-2.4 
(2.41-2.40) 
Rmerge  7.1 (50.3)  3.1 (37.3)  6.2 (34.9) 
I/σ  18.7 (2.4)  30.2 (3)  16.3 (2.2) 
Completeness (%)  98.4 (99.7)  97.1 (85.1)  98.4 (99.8) 
Redundancy  5.3 (5.4)  3.7 (3.7)  3.7 (3.7) 
 
Refinement  R69Q 
 
H150R 
 
R298G 
No. unique relections  43429  23048  29647 
No. atoms: Protein 
                  Ligand 
                  Water 
3848 
69 
216 
3714 
46 
161 
3703 
46 
133 
RWork/RFree 24.5/27.4  24.0/30.0  27.5/29.5 
B-factors (Å
2): Protein 
                       AMP-1 
                       AMP-2 
                       AMP-3 
                       Water 
45.3 
39.9 
40.2 
39.3 
34.4 
53.3 
56.9 
N.B. 
38.5 
48.5 
43.9 
38.5 
N.B. 
43.0 
28.3 
R.m.s deviations from 
standard geometry:  
                 Bond length (Å) 
                 Bond angles (˚) 
 
 
0.010 
1.457 
 
 
0.009 
1.215 
 
 
0.011 
1.331 
Ramachandran plot (%):
favored
outliers
 
96.1 
0 
 
93 
1.5 
 
96.4 
0 
 
Table 3.4A: Crystallographic statistics of the Arg69ÆGln (R69Q), His150ÆArg 
(H150R) and Arg298ÆGly (R298G) mutant models in complex with AMP. The 
highest resolution shell is shown in parenthesis. N.B., no binding. 
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Data collection  R298G R298G R298G R298G 
Method  apo  AMP co-cryst  ADP soak  ATP soak 
Space group  P212121 P212121 P212121 P212121 
Cell dimension:  
a, b, c (Å)
α, β, γ (˚)
 
48.3, 118.7, 129.2 
90, 90, 90 
 
48.5, 121.7, 126.6 
90, 90, 90 
 
48.6, 124.7, 124 
90, 90, 90 
 
49, 123.6, 124.9 
90, 90, 90 
Resolution (Å)  30-2.0 
(2.09-2.00) 
30-2.4 
(2.41-2.40) 
30-2.6 
(2.72-2.60) 
30-2.5 
(2.61-2.50) 
Rmerge  5.8 (43.7)  6.2 (34.9)  5.4 (42.1)  9.2 (44.7) 
I/σ  18.9 (2.5)  16.3 (2.2)  18.1 (2.5)  15 (4.3) 
Completeness (%)  99 (99.3)  98.4 (99.8)  99.1 (99.2)  98.1 (100) 
Redundancy  3.6 (3.6)  3.7 (3.7)  3.6 (3.6)  7.1 (7.3) 
 
 
Refinement  R298G 
Apo 
R298G 
AMP 
R298G 
ADP 
R298G 
ATP 
No. unique relections  51114  29647  23482 24947 
No. atoms: Protein 
                  Ligand 
                  Water 
3837 
46 
280 
3703 
46 
133 
3768 
77 
147 
3801 
85 
85 
RWork/RFree 24.8/26.3  27.5/29.5  24.2/26.1  27.2/30.7 
B-factors (Å
2): Protein 
                       AXP-1 
                       AXP-2 
                       AMP-3 
                       Water 
45.2 
43.1 
N.B. 
43.2 
41.3 
43.9 
66.1 
N.B. 
63.8 
28.3 
54.3 
57.1 
58 
50.4 
45.2 
71.7 
64.5 
61.6 
62.5 
61.9 
R.m.s deviations from 
standard geometry:  
               Bond length (Å) 
               Bond angles (˚) 
 
 
0.008 
1.576 
 
 
0.011 
1.331 
 
 
0.009 
1.304 
 
 
0.010 
1.526 
Ramachandran plot (%):
favored
outliers
 
94.6 
1.7 
 
96.4 
0 
 
95.15 
0.4 
 
 
94.8 
1.5 
 
 
Table 3.4B: Crystallographic statistics of the AMPK-R298G models in the apo form 
or in complex with nucleotides. The highest resolution shell is shown in parenthesis. 
N.B., no binding. 
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The data was processed using Denzo and Scalepack 
210. All crystals belonged to the 
space group P212121. The structures were solved by molecular replacement. The 
starting RWork/RFree were 35/36.6 for Arg69ÆGln, 37.5/38.4 for His150ÆArg and 
35.4/34.9 for Arg298ÆGly.  
 
All three mutant structures are very similar in overall structure to wild type AMPK. 
The most significant differences occur in the γ-subunit with r.m.s.d. in Cα positions 
of 0.4 Å for Arg69ÆGln, 0.7 Å for His150ÆArg and 0.4 Å for Arg298ÆGly. The 
most significant differences occur in the conformation of loops close to the two 
exchangeable nucleotide-binding sites. In His150ÆArg the loop close to site-2 
(residues γ-268 to γ-275) partially occupies the pocket of site-2 which is empty in 
this mutant. In the case of R298G/AMP, the density for some of the residues in this 
loop is poorly defined and these residues were removed from the atomic model. The 
environment of the pockets where AMP-1 and the non-exchangeable AMP-3 are 
situated remains similar.  
 
To summarize, for all three mutant structures, the nucleotide occupancy is 
unambiguous in site-1 and site-3. At site-3 only AMP bound whereas at site-1 AMP, 
ADP or ATP could bind. When I superimpose the mutant structures with wild type 
AMPK, the position of AMP-1 and AMP-3 overlap closely. The fluorescent binding 
studies presented below (see section 4.2.5), will show that the Arg69ÆGln, 
His150ÆArg and Arg298ÆGly mutant AMPK, have reduced affinity for 
nucleotides in one of the two exchangeable nucleotide sites (but that Arg69ÆGln is 
less affected than the other two mutants). The structure of Arg69ÆGln shows clear 
electron density for all three AMP molecules, in contrast there is no electron density 
for AMP in site-2 of the His150ÆArg or Arg298ÆGly structures (Fig 3.12A&B). 
In addition to AMP, Arg298ÆGly was also crystallized with ADP and ATP to 
verify that neither of these nucleotides binds at site-2 (Fig 3.12C). Taken together, 
these data suggests that site-2 is the “weak” site and site-1 is the “tight” site, seen in 
binding measurements (see section 4.2).  
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Figure 3.12: Electron density from initial (Fobs - Fcalc) maps of the AMPK 
mutants: Arg69ÆGln, His150ÆArg and Arg298ÆGly. The binding pocket shown 
is site-2 and the map is contoured at 2.5 σ. The AMP molecules, coloured with 
carbon atoms in yellow sticks, have been transferred from the wild type complex to 
show where the electron density for the nucleotide might be expected, but for the 
His150ÆArg and Arg298ÆGly structures there is no clear electron density for 
AMP. In contrast, Arg69ÆGln does show clear electron density for an AMP 
molecule in site-2. 
 
 
When the wild type structure is compared to the His150ÆArg and Arg298ÆGly 
mutants, an interesting difference is observed in the side chain rotamer of His-297. 
In the wild type structure, the main chain amino group of His-297 hydrogen bonds 
with the phosphate group of the nucleotide in site-2, whereas its side chain interacts 
R298G 
R69Q  H150R   86
with the phosphate of the non-exchangeable AMP-3. In the case of His150ÆArg 
and Arg298ÆGly the side chain of His-297 is rotated 120˚ with respect to the wild 
type and occupies a position that would sterically clash with the phosphate of 
AMP-2 if it were occupied. (Fig 3.13). In contrast, in the structure of Arg69ÆGln, 
His-297 adopts the same side chain rotamer as wild type.  
Arg69ÆGln                                      His150ÆArg 
    
 
 
Arg298ÆGly 
 
Figure 3.13: Ribbons representation of the superposition between wild type and 
mutant mammalian AMPK structures: wt protein is in cyan; a) Arg69ÆGln in 
yellow b) His150ÆArg is in green. c) Arg298ÆGly is in purple. AMP molecules 
are shown in stick representation together with residues important in nucleotide 
binding. 
 
AMP-2
H297 
H150 
AMP-3 AMP-2
H297 
R69 
AMP-3 
AMP-2
H297
R298
AMP-3
A  B 
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The crystal structures of the three WPW mutants complement the results from the 
binding studies in section 4.2.5. My binding data was produced with the use of two 
fluorescence reporters, mant-AMP and NADPH, and suggests that the two 
exchangeable nucleotide binding sites have different affinities. Additionally, in 
WPW mutants AMP has a reduced affinity for the “weaker” site, compared to wild 
type protein. Arg69ÆGln appears to be the protein that is least affected by the 
mutation. Since the crystal structures in this chapter show no nucleotide bound in 
site-2 for Arg298ÆGly and His150ÆArg, I can speculate that, at least in the 
truncated construct, the weaker site is site-2, whereas the tighter site is site-1.  
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4. Results – binding studies 
4.1 Identification & quantification of nucleotide bound to WPW mutant AMPK 
Bound nucleotide analysis on a purified wild type AMPK sample, shows that for 
every wild type protein molecule there is approximately 0.85 molecules of AMP and 
0.15 of ADP 
213. These nucleotides therefore bind sufficiently tightly that they 
co-purify with the enzyme through the various steps of protein purification. To 
determine whether the WPW mutations affect the binding of AMP in the 
non-exchangeable site-3, I carried out the same analysis on the Arg-298Æ Gly, 
His-150ÆArg and Arg-69ÆGln mutants. AMPK mutants were denatured, protein 
removed by centrifugation and the supernatant analyzed by high-performance 
liquid-chromatography (HPLC). In the three mutants, about 75% of the 
adenyl-nucleotide present is AMP and about 17% is ADP (Fig 4.1). This suggests 
that in WPW mutants, as seen wild type protein, AMPK co-purifies with one AMP 
molecule. 
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Figure 4.1: The elution profile for the supernatant from the Arg-298ÆGly protein 
only is shown. (A) The protein is in the apo form and the concentration is 220 µM. 
Peak 1 & 2 elute in the same position and with the same absorbance spectrum as 
AMP and ADP and their concentrations were 165 µM and 37.8 µM, respectively. In 
(B), 217 µM ATP was added to the protein sample prior HPLC analysis to calibrate 
the system. The areas under the AMP, ADP and ATP peaks were measured. These 
results imply that AMPK co-purifies, with AMP in a 1:1 stoichiometry. 
 
 
Peak 1 = AMP 
Peak 2 = ADP 
Peak 1 = AMP 
Peak 2 = ADP 
Peak 3 = ATP 
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4.2 Fluorescence studies 
4.2.1 Overview 
The crystal structure of truncated mammalian AMPK shows that three adenine 
nucleotide molecules bind to the γ subunit of AMPK. One binding site (site-3) has 
been shown to contain non-exchangeable AMP (site-3) as just described. The other 
two binding sites are exchangeable in that AMP, ADP or ATP can bind 
competitively. Characterizing the binding properties of these two sites is likely to be 
important for understanding how AMPK activity is regulated. Although not a 
quantitative measure of binding affinity, site-1 consistently shows stronger electron 
density for bound nucleotide ligands than site-2 in my crystallographic studies, 
suggesting at least that the two sites behave differently. The main focus of this 
chapter is to establish the affinities of nucleotides for the two exchangeable binding 
sites in AMPK and whether these sites display a reduced affinity for nucleotides in 
WPW mutants. The binding of nucleotides to the two exchangeable sites of AMPK, 
as monitored by a fluorescently-labelled AMP, can be represented schematically as 
such. 
 
Figure 4.2: Schematic representation of nucleotide binding to AMPK: Site-3 is 
non-exchangeable and mostly contains AMP. The fourth potential site is always 
empty. Site-1 and -2 are the two exchangeable sites, where α  is the cooperativity 
factor, if α  > 1 there is positive co-operativity between ligands binding in the two 
sites; if α < 1 then there is negative co-operativity.   
site-3 
non-ex
site-2
site-1 empty 
site
AMP
Kd
= 
mant-AMP 
Kd1 
Kd2α  Kd1α 
AMP 
AMP   90
 
 
In general it is simplest to assume that a binding event is non-cooperative, both 
energetically (i.e., α =1) and spectroscopically (i.e., that the optical properties of the 
ligand in one site are not affected by occupancy of the other site) (discussed later in 
section 5.3). Indeed, most analysis methods work on this assumption. The 
fluorescence signal observed for a mixture of AMPK (P) and ligand (L) will be 
given by the following equation: 
 
F  = FL[L] + FPL1[PL1] + FPL2[PL2] + FPL1,2[PL1,2] 
where the F values are molar fluorescence coefficients, L1 represents a ligand 
binding to site-1, L2 to site-2 and L1,2 to ligands binding to both sites. The terms in 
square brackets are concentrations, the values of which depend on total 
concentrations and on the Kd values. What will be observed in any particular 
fluorescent titration therefore depends not only on the individual Kd values but also 
on how much of the total fluorescence change is contributed by binding at a 
particular site. Essentially, the equation means that the fluorescent signal obtained is 
the sum of the fluorescence obtained from the fluorescent reporter uncomplexed, in 
complex with one or the other site and when bound in both sites. A successful 
analysis for two Kd values requires accurate determination of the F values. If the two 
sites have significantly different affinities it is unlikely that the F value for the 
complex with a single ligand molecule in the low affinity site will be determinable. 
The reason for this is illustrated in Fig 4.3 which shows how concentrations of 
different species vary for the two possible titration ‘modes’: titration of the ligand 
with the protein (A) and titration of the protein with the ligand (B).  
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Figure 4.3: Schematic representation of how concentrations of different species vary 
for the two possible titration ‘modes’: titration of the protein with the ligand (A) and 
titration of the ligand with the protein (B). In this simulation the dissociation 
constants (Kds) for sites 1 and 2 were set arbitrarily at 1 and 5 μM, respectively. The 
concentration of the ligand (in A) and protein (in B) were held constant at 2 μM. 
Interestingly, the two simulations demonstrate how approaching the experiment in 
different ways might show different proportions of the two species. 
 
The key point is that in either case the fraction of total protein with a single ligand in 
the low affinity site remains low throughout the course of the titration and this 
species cannot therefore be fully characterized in terms of Kd or optical properties. 
(μM) 
(μM)   92
Consequently, any binding curve for AMPK obtained with a fluorescent reporter that 
monitors two sites with significantly different affinity it is likely to provide 
relatively little information about the lower affinity site. 
 
4.2.2 Identification of NADPH as a fluorescent reporter for AMPK 
Previous activity studies on AMPK showed that low micromolar concentrations of 
AMP cause allosteric activation of the protein 
85,229. These enzymatic assays were 
carried out using different techniques, but typically employed radioactively labeled 
[γ-
32P]ATP. My attempts to reproduce the effects of AMP on AMPK using the 
pyruvate kinase – lactate dehydrogenase coupled enzyme assay system 
230 were 
unsuccessful in the sense that very high concentrations of AMP were required to 
activate AMPK. A possible explanation for this was that one of the ingredients in the 
coupled assay mixture was interfering with AMP binding to AMPK. Because the 
assay contains high concentrations of NADH and given the structure of NADH (Fig 
4.4), I decided to investigate NADH binding to the enzyme.  
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Comparison of the structures of AMP (a), NADH (b) and NADPH (c). 
The parts that confer fluorescence properties to the nucleotide are circled in red. 
 
 
NADH is a physiologically important nucleotide whose structure is similar to AMP, 
but with an additional group extending from the phosphate moiety. NADPH is 
   HO  OH 
a 
b 
c   93
similar to NADH but has an extra phosphate group linked to the 2’ position of the 
ribose (Fig 4.4). The nicotinamide group is responsible for the fluorescence of these 
nucleotides.  
 
The binding of NADH and NADPH to AMPK was monitored by adding protein to a 
solution of the nucleotide (10 µM) in Tris buffer. Free (uncomplexed) NADPH has 
an emission maximum at 461 nm. Addition of AMPK blue-shifts the fluorescence 
maximum to 428 nm and increases the signal approximately 9-fold (Fig 4.5A). The 
signal enhancement is significantly less for NADH (Fig 4.5B). To determine the 
stoichiometry of NADPH binding to AMPK, I carried out some titrations with the 
nucleotide in buffers with no salt and/or at a temperature of 4˚C. These conditions 
were chosen with the idea of increasing the binding affinitiy and therefore making 
the determination of the stoichiometry clearer. Interestingly, the stoichiometry 
between NAD(P)H and AMPK is 1:1 (Fig 4.5C). 
 
To confirm that the binding properties of the crystallized construct were similar to 
those of the full-length protein, both proteins were analyzed under the same 
conditions. Because the protein are routinely stored in a buffer containing 100mM 
NaCl, the majority of titrations were performed in a buffer with 100mM NaCl in 
order to keep the ionic strength of the solution constant. Affinities were determined 
from plots of fluorescent intensity at 440 nm as a function of protein concentration. 
The fluorescent emission was monitored at 440 nm because this is the wavelength 
where the difference in fluorescence intensity between free and bound NADPH is 
greatest. Both full-length AMPK and the truncated construct bind NADPH similarly 
with 1:1 stoichiometry and an affinity of 19 ± 2.5 μM (See Appendix 1.1). Having 
established the properties of NADPH binding to AMPK, I then examined the effects 
of AXPs as potential competitors of NADPH binding. Such competition experiments 
with AXPs showed that the site which is competing with NADPH binds AMP, ADP 
or ATP with affinities of 3.3 ± 0.6 μM, 1.3 ± 0.2 μM and 1.1 ± 0.2 μM, respectively 
(Fig 4.5C; Table 4.1 & Appendix 1.2).   94
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Figure 4.5: Fluorescence emission scans for the titration of NADPH (a) or NADH 
(b) with AMPK with an excitation wavelength of 340 nm. AMPK binding of 
NADPH produces a fluorescence signal change more than two-fold larger than that 
seen with NADH. (c) Titration of 10 μM NADPH with AMPK done at low ionic 
strength (red) and in 100 mM NaCl (blue); A representative competition experiment 
with ATP is shown in green. The solid line represents the best fit to the data for 
AMPK with a one-site model for NADPH. Evidently the one site model provides 
very good fit to the experimental data and as such there is no reason to fit the data to 
a two site model. This analysis does not, of course, preclude the possibility that there 
is a second, much weaker site, that is not significantly occupied under the 
experimental conditions.   95
 
 
 
 
 
 
 
Nucleotide   Kd (μM) 
  Direct  Displacement
AMP  3.3 ± 0.6  2.2 ± 0.3 
ADP  1.3 ± 0.2  0.8 ± 0.2 
ATP  1.1 ±.0.2  1.3 ± 0.3 
 
 
Table 4.1: Dissociation constants for the interaction of wild type AMPK with 
different NADH/NADPH (A) and AXPs (B) at the tighter site. AXP competition 
experiments were done in 100 mM NaCl. 
 
NADPH and NADH bind to AMPK with similar affinities which are 5-20-fold 
weaker than those for AXPs. I also tested the binding of the non-fluorescent 
oxidized forms of the nucleotides NAD
+/NADP
+ in competition assays. 
Interestingly, NAD
+ and NADP
+ bind to AMPK much weakly than the reduced 
forms. The dissociation in 100 mM NaCl constants were estimated to be 156 
± 6.7 μM (NAD
+) and >1 mM (NADP
+) compared with 18.3 ± 2 μM and 
19 ± 2.5 μM for the reduced forms under the same conditions. 
 
The affinities of nucleotides can also be determined using displacement experiments 
(see Appendix 1.2). In this case a mixture of 30 µM of AMPK, 30 µM NADPH and 
200 µM of AMP, ADP or ATP is titrated into a solution containing the same 
concentration of protein and NADPH but no AXP. With increasing concentration of 
AXP the NADPH is displaced from its binding site and the fluorescence signal 
decreases accordingly. The Kds determined by displacement experiments are in good 
agreement with my previous competition experiments (Table 4.1B) (Fig 4.6). 
Nucleotide Kd (μM)
NADH (low salt) 7.4 ± 3.3
NADPH (low salt) 2.9 ± 0.3
NADH (100mM NaCl) 18.3 ± 2
NADPH (100mM NaCl) 19 ± 2.5
B 
A   96
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Figure 4.6: Displacement of NADPH by AXPs from AMPK. The concentration of 
AMPK and NADPH remained constant throughout the experiment (30 µM). 
Experiments were carried out using an excitation wavelength of 340 nm and the 
fluorescent signal at 440 nm was used to monitor the fraction of bound NADPH. 
 
To test whether the affinities of AMPK for nucleotides change upon phosphorylation 
state of the enzyme, I carried out binding studies using phosphorylated full-length 
AMPK. Full-length AMPK was phosphorylated by incubation overnight with a 
constitutively active form of CaMKKβ. Constitutively active CaMKKβ is produced 
by expressing a truncated form of the protein missing its autoinhibitory domain. 
Consequently, AMPK is fully phosphorylated on Thr-172 with additional 
auto-phosphorylation sites. NADPH binds phosphorylated AMPK with a similar 
affinity to that of the un-phosphorylated form (Kd = 25 ± 3 μM). The competition 
and displacement experiments described above were used to determine Kd values for 
the binding of AXPs to the phosphorylated protein: 2.6 ± 2.1 μM for AMP, 
2.5 ± 0.39 μM for ADP and 3.4 ± 2.1 μM for ATP. Thus, the affinity of AMPK for 
AXPs for phosphorylated protein remains essentially unchanged, compared to the 
un-phosphorylated form, at least for the site that is monitored by NADPH. 
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4.2.3 Mant-nucleotides  
Having established the binding affinity of one of the two exchangeable sites, I 
carried out a series of experiments to determine the properties of the second site. The 
use of mant-labelled AMP or ATP was mainly used for this study. The structure of 
mant-nucleotides consists of an AXP molecule with a mant group linked to the 
ribose at either at the 2’ or 3’ position (Fig 4.7). The mant group gives the nucleotide 
fluorescent properties. One of the advantages of using this fluorophore is its 
relatively small size, which should minimize any perturbation of binding properties 
231. Although our crystal structure shows that there is an aspartic acid that interacts 
with the ribose moiety of the nucleotide in each of the three sites (γ-89, γ-244 and 
γ-316), it is evident from my co-crystallization structure of AMPK/mant-AMP that 
the modified AMP binds in much the same way as unmodified AMP (section 3.2.4). 
 
 
 
Figure 4.7: Comparison of the structures of AMP (a) and mant-AMP (b). The part 
that confers the fluorescence properties to the nucleotide is circled in red. 
 
 
When excited at a wavelength of 380 nm, the uncomplexed mant-nucleotides have 
an emission maximum at 449 nm. In the presence of saturating AMPK the emission 
maximum is slightly blue-shifted to 441 nm and the fluorescence intensity is 
increased ca. 2-3 times (Fig 4.8A). Binding of mant-nucleotide was initially 
a  b   98
monitored by titrating 10 µM solutions of mant-AMP or mant-ATP with AMPK in 
Tris buffer with and without 100 mM NaCl. Experiments performed at low ionic 
strength gave more definitive information on stoichiometry because of the higher 
affinity for the ligand under these conditions. The change in the fluorescence signal 
was largest at 438 nm and this wavelength was used to monitor binding. Kd values 
were calculated from the resulting curves (Fig 4.8B).  
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Figure 4.8: Fluorescence emission scan for a titration of mant-AMP with AMPK 
with an excitation wavelength of 380 nm (A). The 438 nm value from each curve 
was used to estimate the affinities for mant-AMP (B). 
[AMPK]   99
 
To confirm that the binding properties of the crystallized construct are similar to 
those of the full-length protein the two proteins were analyzed under the same 
conditions (Fig 4.9). These fluorescence titrations clearly indicate that AMPK binds 
two molecules of mant-nucleotide. The dissociation constants were determined using 
standard methods with the assumption that the two binding sites were non-
interacting, both energetically (α=1) and spectroscopically. The analysis did not 
assume that the two sites were identical nor that binding at the two sites generates 
the same fluorescence change. Analysis shows that mant-AMP displays somewhat 
different binding at the two exchangeable sites of AMPK in 100 mM NaCl with 
estimated Kds of 31 ± 8 µM and 52 ± 15 μM, respectively. In contrast, mant-ATP 
appears to have significantly different affinities for the two sites with  Kds of 5.8 
± 2 µM and 50 ± 12 µM. Because of the low affinity binding of mant-nucleotides for 
the weaker site, the resulting Kd values have large errors. The same experiments 
were carried out at low ionic strength (no added salt) and the affinities of mant-AMP 
for the two sites were 10.4 ± 3 µM and 10.8 ± 5 μM. The affinities of mant-ATP for 
the two sites under low salt conditions were again significantly different with Kds of 
0.7 ± 0.6 µM and 15.2 ± 5 µM. In contrast to the studies performed with NADPH, 
which monitors only one binding site, mant-nucleotides bind to two sites with 
different affinities. Unfortunately, this means that the binding constants for the 
unlabelled ligands are complicated to extract using either competition or 
displacement assays. 
   100
 
Figure 4.9: Titration of mant-AMP with AMPK at low ionic strength: full length 
(open circles) and truncated protein (closed circles). The dashed and solid lines 
represent the best fit for full length AMPK using one- and two-site binding models, 
respectively. 
 
Fluorescence binding studies were also performed using FRET (Förster resonance 
energy transfer) based assays with mant-AMP as the reporter (see Appendix 1.3) 
223-
224. The use of FRET provides an alternative method for estimating the Kd values for 
the two sites and has the added advantage of using much less protein for each 
experiment. In this approach, binding of nucleotides to AMPK was monitored by 
adding mant-AMP to a solution of AMPK, rather than vice versa. Salt concentration 
remained constant throughout the experiment at 100 mM. Fluorescence emission 
scans from 400 to 550 nm were recorded as described earlier except that the 
excitation wavelength was 290 nm to take advantage of energy transfer from 
AMPK’s tryptophan residues to the mant group (Fig 4.10A). Changes in 
fluorescence intensities at 440 nm were used to estimate Kd values (Fig 4.10B). The 
estimated affinities of mant-AMP for AMPK in the presence of 100 mM NaCl were 
5.5 ± 3 µM and 10.5 ± 5 μM. Although the values for the two sites are similar, they 
are quite different from those determined using the alternative titration ‘mode’ 
(adding AMPK to mant-AMP). This is most likely to be associated with the   101
difficulty in extracting the molar fluorescence intensities from the previous data (see 
section 4.2.1).  
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Figure 4.10: Fluorescence emission scans from 400 – 550 nm for the fluorescent 
titration of AMPK with mant-AMP performed using FRET. Experiments were 
carried out using an excitation wavelength of 290 nm (A). The 440 nm value from 
each curve was used to estimate the Kds (B). 
 
The FRET technique can also be applied with displacement or competition assays in 
order to estimate the binding constants for unlabelled nucleotides. In a typical 
experiment, 10 µM AMPK, 60 µM mant-AMP and 400 µM AMP, ADP or ATP 
were added to a solution containing 10 µM AMPK and 60 µM mant-AMP. Protein 
[AMPK]   102
and mant-AMP concentrations therefore remain constant throughout the experiment. 
The use of a large excess of mant-AMP ensures that the weaker site is also at least 
partially occupied and this will then be displaced when increasing amounts of AXP 
are added. Emission scans from 400 to 550 were performed as above (Fig 4.11A) 
and the decrease in fluorescence intensity at 440 nm was monitored. 
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Figure 4.11: Fluorescence emission scan from 400 – 550 nm for a titration of 
mant-AMP/AMPK mixture with AXP. The concentrations of AMPK (10 μM) and 
mant-AMP (60 μM) remain constant throughout the titration. Experiments were 
carried out using an excitation wavelength of 290 nm (A). The 440 nm value from 
each curve was used to estimate the affinity of the nucleotides (B). 
[AMPK] = 10 μM 
[mant-AMP] = 60 μM 
[AMPK] = 10 μM 
[mant-AMP] = 60 μM   103
 
From the titration curve (Fig 4.11B) it can be seen that ATP binds more tightly than 
AMP to the high affinity site but somewhat more weakly than AMP to the low 
affinity site. Unfortunately, these displacement experiments with unlabelled 
nucleotides proved to be somewhat less informative than I had hoped. This is largely 
due to the uncertainty in the Kd values for the binding of mant-AMP to the two, 
particularly the weaker, sites (see above). Nonetheless, it is clear that the 
displacement of mant-AMP observed at low added [AXP] is consistent with AXP 
binding with low micromolar affinity to the higher affinity site, as also determined in 
the experiments with NADPH. The best that can be said about the binding of AXPs 
to the lower affinity site is that the Kd for AMP is probably in the range 20-40 μM 
and that the binding of ATP to this site is somewhat weaker, perhaps in the range 
40-70 μM. What is particularly clear from these studies is that the mant-nucleotides 
(particularly mant-AMP) do not bind with the same affinity as the unlabelled 
nucleotides. 
 
4.2.4 The magnesium effect on AMPK 
Initially, in our lab the structure of AMPK with bound ATP was obtained by soaking 
crystals of AMPK/AMP with Mg
2+-free ATP. (EDTA was used as a Mg
2+ chelator). 
The resulting structure showed the presence of Mg
2+-free ATP, as was also reported 
for the yeast homologue 
113. The fluorescence studies detailed below show that 
magnesium is not required for ATP binding by AMPK, but that both free-ATP and 
Mg
2+-ATP bind to AMPK with similar affinity. Only titrations of mant-ATP at very 
high Mg
2+ concentrations (1.25, 2.5, 5 and 10 mM) somewhat reduced the affinity of 
the protein for the nucleotide (Fig 4.12). However, this effect may not be 
physiologically relevant because the cellular concentration of free-Mg
2+ may be as 
low as 0.4mM 
232. In the presence of as much as 125 μM of the metal ion, the 
fluorescence titration is similar to the one observed in the absence of Mg
2+. This 
concentration of the metal ion would virtually saturate the ATP present in the 
binding assay (Kd around 10-50μM) 
232. These results agree with earlier studies on 
ATP binding to AMPK which concluded that the affinity of the enzyme for ATP is   104
independent of magnesium 
16. Further soaking experiments of AMPK/AMP crystals 
in Mg
2+-ATP were performed and the new electron density maps showed, in 
addition to the non-exchangeable AMP, the presence of two Mg
2+-ATP molecules in 
the same nucleotide binding sites where previously there were Mg
2+-free ATP or 
AMP. The structures of AMPK in complex with Mg
2+-ATP and the one with 
free-ATP are very similar and thus confirm that ATP binding to AMPK is 
magnesium-independent. The metal ion does not interact directly with the protein, 
but with the β- and γ-phosphates of the nucleotide. 
 
Figure 4.12: Titration of AMPK with 10 μM mantAMP with in the presence of 0 
mM(open circles), 0.125 mM (closed circles), 1.25 mM (triangles), 2.5 mM 
(squares), 5 mM (diamonds), and 10 mM MgCl2 (closed squares). 
 
 
4.2.5 AMPK mutations which cause Wolff-Parkinson-White syndrome (WPW) 
Fluorescence spectroscopy was also used to study naturally occurring AMPK 
mutations which cause WPW, a glycogen storage cardiomyopathy 
186 (see section 
1.1.5.2). It is assumed that these mutations interfere with normal activation of the 
enzyme by affecting the protein’s affinity for regulatory nucleotides 
232. These 
mutations are found in the γ-subunit, mainly close to the nucleotide binding sites.   105
The mutations I have studied are Arg69Gln, His150Arg and Arg298Gly. These 
mutants were selected because they are the most common and the most widely 
studied. Our previous wild type AMPK structure 
213 shows that these mutations are 
situated close to the nucleotide binding pockets and that these mutated residues 
interact with the phosphate groups of AMP or ATP (Fig 4.13). See section 3.2.5 for 
the crystal structures of these mutants.  
 
Figure 4.13: Interactions between AMP molecules and three of the basic residues 
which, if mutated, cause a glycogen storage cadiomyopathy. 
 
After I made the relevant constructs, I expressed and purified the proteins with 
which I carried out the fluorescent binding studies. The first experiment looked at 
NADPH binding to the mutants. NADPH binds to Arg69Gln, His150Arg and 
Arg298Gly in 100 mM NaCl with estimated dissociation constants of 53 ± 6 μM, 27 
± 4 μM and 31 ± 4 μM, respectively, compared to 19 μM for wild type (see Table 
4.1, pag81). Competition experiments carried out with NADPH as a reporter show 
that AMP, ADP and ATP have dissociation constants for the NADPH-monitored site 
of 7.3 ± 2.1 μM, 3.1 ± 1.0 μM and 5.2 ± 1.1 μM for the Arg69Gln mutant. The 
dissociation constants of AMP, ADP and ATP for His150Arg are 2.1 ± 0.4 μM, 0.9 
± 0.3 μM and 1.1 ± 0.2 μM and those for Arg298Gly are 7.5 ± 0.8 μM, 2.2 ± 0.3 μM 
His-150 
AMP 1 
AMP 3 
AMP 2 
Arg-69 
Arg-298   106
and 1.6 ± 0.2 μM (Table 4.2). Somewhat surprisingly perhaps, AXPs still bind to 
this site with similar affinities as the wild-type. 
 
 
 
 
 
Table 4.2: Kd values for the interaction of nucleotides with site-1 of wild type and 
mutated AMPK. The truncated construct was used for these experiments. All the 
units are in μM. 
 
Measurements on WPW mutants were also performed with mant-AMP in order to 
address the question of the stoichiometry of binding. Titrations of mant-AMP with 
AMPK showed that all three mutants (Arg69Gln, His150Arg and Arg298Gly) bind 
two molecules of mant-AMP. Measurements using FRET based assays gave similar 
results (Fig 4.14A and Table 4.3).  
 
The affinity of mant-AMP for the strong site appears to be significantly weakened 
for His150Arg and Arg298Gly. This observation is apparently different to the results 
obtained with NADPH for the effect of these mutations on the affinities for AXPs 
(see above). Of course it must be remembered that the effect on the binding of an 
AXP may be different from the effect on the fluorescently labeled analogue. It 
appears that the mutations also affect the affinity of mant-AMP for the weaker site, 
with two-fold, eight-fold and eleven-fold reduced affinity for Arg69Gln, His150Arg 
and Arg298Gly, respectively.  
 
Displacement experiments of mant-AMP by AMP and ATP with mutant AMPKs 
display behavior similar to that observed with the wild type and it appears that ATP 
binds more tightly than AMP to the high affinity site but somewhat more weakly 
than AMP to the low affinity site (Fig 4.14B). As mentioned above, Kd values for 
unlabelled nucleotides cannot be accurately calculated from these experiments.  
AMP ADP ATP
wt 3.3 ± 0.6 1.3 ± 0.2 1.1 ±.0.2
R69Q 7.3 ± 2.1 3.1 ± 1.0 5.2 ± 1.1
H150R 2.1 ± 0.4 0.9 ± 0.3 1.1 ± 0.2
R298G 7.5 ± 0.8 2.2 ± 0.3 1.6 ± 0.2  107
Nonetheless, they are consistent with Kds in the low micromolar range for the tighter 
site and tens of micromolar for the weaker site. 
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Figure 4.14: Fluorescence titrations of mant-AMP with AMPK using an excitation 
wavelength of 290 nm. (A) In the direct experiment increasing concentrations of 
mant-AMP were added to a solution of AMPK (10 µM). (B) Displacement of 
(60 µM) mant-AMP by AMP and ATP in wild type and mutated AMPKs (10 µM). 
Only data for the Arg298Gly mutant only is shown in the figure. The 440 nm value 
from each curve was used to estimate the affinity of mant-AMP.   108
 
 
 
 
 
Table 4.3: Kd values for the interaction of wild type and mutated AMPK with 
mant-AMP in the tighter and weaker sites. All the units are in μM. 
 
 
The fluorescence binding studies with the two fluorescence reporters (NADPH and 
mant-AMP) agree to the extent that the two exchangeable nucleotide binding sites 
have different affinities for AXPs. Within the same binding site, AMP, ADP and 
ATP bind with similar affinity. The WPW mutants seem to have a reduced affinity 
for AMP in both exchangeable sites, but especially in the weaker site. Therefore 
nucleotides do bind but the preferential binding of ATP relative to AMP in both sites 
and the reduced affinity of AMP for the weak site will eventually help to explain the 
phenotype of WPW syndrome (see section 5.8). 
 
 
4.2.6 Phosphopeptide 
Under cellular homeostasis the concentration of Mg
2+-ATP is around 2-5mM. AMP 
and ADP, which are largely magnesium-free because they bind magnesium with 
lower affinity, are around 2-5 μM and 200-500 μM, respectively 
232. Given the 
binding constants described above, the γ-subunit of AMPK would be mostly bound 
to Mg
2+-ATP and the majority of the enzyme would therefore be inactive; only a 
tiny proportion of AMPK (<<1%) would be in the AMP-bound form. When cells are 
subject to stresses, such as physical exercise, there is a small rise in AMP levels 
87. It 
is thought that AMP concentrations increase by perhaps 2-3-fold at most. This 
increase in AMP would cause a similar fold increase in the AMP-bound form of the 
kinase. When the enzyme is AMP-bound there is an increase in the amount of 
phosphorylation at Thr-172 of the α-subunit 
38, probably due to reduced rates of 
mant-AMP
wt 5.5 ± 1.3 & 10.5 ± 2.2
R69Q 2.5 ± 0.6 & 21.8 ± 3.5
H150R 15 ± 6 & 86 ± 21
R298G 9.2 ± 2.4 & 119 ± 24  109
dephosphorylation 
232. Phosphorylation of Thr-172, which is within the activation 
loop of the kinase domain, activates AMPK. At present, the mechanism of 
propagating signals from ATP/AMP binding at the regulatory γ subunit to the kinase 
domain is unclear. Given that the nucleotide binding sites on the γ subunit are 
markedly basic, it occurred to me that the phosphorylated activation loop of the 
kinase might, under some circumstances, interact with it. In order to test this idea, a 
phosphopeptide of 20 residues (NMMSDGEFLRT(P)SCGSPNYAA) from the 
activation loop of the kinase domain was studied using the crystallized construct. 
The peptide has a phosphothreonine at the position corresponding to the 
physiological phosphorylation site at Thr-172. Titrations of labeled nucleotides 
(either mant-AMP or NADPH) with AMPK were essentially identical in the 
presence and absence of this phosphopeptide (Fig 4.15). This was the case even 
when the peptide concentration was as high as 1 mM, suggesting that the 
phosphopeptide does not bind at the nucleotide binding sites in the γ subunit. The 
recent crystal structure from our lab of an AMPK construct that includes the kinase 
domain shows that the phosphorylated Threonine forms a strong interaction with the 
kinase domain that orders the otherwise disordered activation loop. In the light of 
this result, and given what is known about the effects of phosphorylation of kinase 
activation loops of this sort of kinase, the idea behind my peptide experiment seems 
naïve in retrospect. 
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Figure 4.15: Fluorescence titrations of mantAMP (A) and NADPH (B) with AMPK 
in the presence and absence of the phosphopeptide. Each point represents the 
438 nm value from the emission scan. There is no competition detectable at either of 
the exchangeable binding sites. 
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4.2.7 Binding characterization of C05-1 and ZMP compounds 
In the next section of this chapter I will describe how I identified a novel small 
molecule compound that binds to AMPK – C05-1 (see section 4.3.4). Fluorescence 
studies were also undertaken to provide insight into how C05-1 might interact with 
AMPK. Titration experiments with AMPK and mant-AMP both in the presence of 
50 μM C05-1 did not work because the fluorescence signal was variable and 
unstable, probably due to aggregation caused by the compound. Titrations of AMPK 
with NADPH in the presence and absence of C05-1 were essentially identical (Fig 
4.16) and suggest therefore that C05-1 does not compete with AXP binding at the 
tighter site. 
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Figure 4.16: Titration of NADPH with AMPK in the presence and absence of 
C05-1. 
 
ZMP has been a valuable tool to investigate AMPK regulation as it mimics the 
effects of AMP (i.e. allosteric activation and reduced dephosphorylation) (see 
section 1.3.2) (Fig 3.6). However, this compound is not completely specific for 
AMPK, as ZMP interacts with other AMP-sensitive enzymes. Titration experiments 
with ZMP in competition assays with NADPH, which monitors the tighter of the two   112
exchangeable sites, suggest a Kd of 18 ± 1.2 µM (Fig 4.17). Interestingly, the 
affinity of this activator is therefore about five-fold weaker than that of AMP for 
site-1. Displacement experiments with mant-AMP were performed in an attempt to 
assess the affinity of ZMP for site-2. However, binding of ZMP at this site is 
evidently very weak and a Kd value could not be determined, suggesting that the 
affinity is weaker than 200-300 µM. The low affinity of ZMP for AMPK compared 
with that of AMP limits the physiological utility of this compound as a drug. It 
remains however a useful tool for biochemical studies. See section 3.2.3 for the 
crystal structure of AMPK in complex with ZMP. 
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Figure 4.17: Titration of NADPH with AMPK in the presence and absence of ZMP. 
ZMP shows a significantly reduced affinity compared with AXPs. 
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4.3 Thermal stability shift measurements 
4.3.1 Overview 
This section describes how I tested a list of compounds, selected from an in silico 
screen, carried out by our colleagues at MRCT, for binding to the regulatory subunit 
of AMPK. Fluorimetry is a time-consuming technique that requires larges amount of 
highly concentrated protein for each experiment, therefore it would not have been 
practical to test >400 compounds with a fluorimeter. In contrast, thermally induced 
unfolding is a technique that requires small quantities of protein per experiment. 
This technique can be useful for the study of protein stability, and since the stability 
of a protein is altered when ligands bind, such studies can be used to screen for 
novel ligands 
233. Therefore I monitored AMPK unfolding by detecting the increase 
in turbidity as the protein aggregates following unfolding at high temperatures. It is 
not ideal to monitor turbidity but given that it is what happens on heating a protein 
sample I did not have any choice. Solution turbidity can be monitored at sufficiently 
high wavelength to avoid interference in the measurements from 
nucleotide/compound absorption. The binding of these ligands is compared to the 
natural ligands, AMP & ATP and a known AMPK activator, A-769662. 
 
The shape of the thermal unfolding curve for AMPK is sigmoidal (Fig 4.18). The 
absorbance remains unchanged until the sample reaches the temperature at which the 
protein starts to unfold (~51 ºC for AMPK). The turbidity then increases and 
eventually reaches a plateau when most of the protein present has unfolded and 
precipitated. The midpoint of the curve is used as a reference point for comparing 
the stability of different protein samples because, when a protein is rendered more 
stable, there is a shift of the curve to the right (i.e. to a higher temperature) and the 
Tm value is increased (See Appendix 2.1).   114
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Figure 4.18: Typical sigmoidal curve for the thermal unfolding of AMPK. 
The midpoint is indicated in red. 
 
 
4.3.2 Natural ligand stabilization 
Thermal denaturation was measured at different AMP and ATP concentrations 
(25 μM, 50 μM, 100 μM, 200 μM, 400 μM, 800 μM, 1.7 mM and 4.5 mM). The 
results show that ATP and AMP stabilize the AMPK to a similar extent, confirming 
that these nucleotides bind to AMPK with similar affinities (Fig 4.19). At higher 
nucleotide concentrations, there is a larger the shift of the midpoint of the unfolding 
curve (Table 4.4). The average Tm of the unliganded AMPK is 53.1ºC, but this value 
can increase up to 62ºC with 4.5 mM AMP. The affinity of ligands at the melting 
point can be estimated if the unfolding constant is known, but this Kd is very 
different from the one at room temperature, as binding affinities of ligands for 
proteins get substantially weaker with increasing temperatures (see Appendix 2.2). 
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Figure 4.19: Thermal shift assay result for truncated AMPK in the presence of AMP 
(a) and ATP (b). The control curve (protein sample without nucleotide) is in black. 
A significant shift in the curves to the right is observed as nucleotides are added to 
the protein sample. The higher the ligand concentration, the bigger the shift of the 
curve. The protein sample with 4.5 mM ATP (not shown) is unstable and 
precipitates before the control sample. 
           Tm (ºC)
Concentration (mM) AMP ATP
0 53.1 53.1
0.025 54.8 55.2
0.05 55.7 55.6
0.1 56.1 56
0.2 56.6 56.2
0.4 57.4 57.1
0.8 58.8 58.2
1.7 60.6 60.2
4.5 62 ND  
Table 4.4: Midpoint temperatures of the protein-unfolding transition (Tm) for 
AMPK in the presence of nucleotides. 
 
4.3.3 Drug-induced stabilization 
The stabilizing effect of the activator drug A-769662 was also examined at different 
concentrations (125 μM, 250 μM, 370 μM and 490 μM) (Fig 4.20). The behavior 
was similar to that observed with AMP and ATP (Table 4.5). Interestingly, the drug   116
stabilizes AMPK to a smaller extent than nucleotides since 250 μM A-769662 
produces approximately the same shift as that induced by 50 μM AMP. It is difficult 
to interpret why AMP and A-769662 stabilize AMPK so differently, because the 
melting point of a protein is influenced by many factors such as the affinity for the 
ligand and the number of binding sites. At time of writing, the specific binding site 
for A-769662 has not been published. It is possible that A-769662 binds in one or 
more sites other than the nucleotide binding sites given its generally hydrophobic 
nature. 
 
Figure 4.20: Stability measurement of AMPK in the presence of A-769662 
compound. The control curve is indicated in black.   
 
Concentration (μM) Tm (ºC)
0 53.1
125 54.8
250 55.7
370 56.1
490 56.6  
Table 4.5: Midpoint temperatures of the unfolding curve (Tm) of AMPK in the 
presence of varying concentrations of A-769662. 
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4.3.4 Discovery of a new binding compound: C05-1 
Once the crystal structure of the trimeric complex used for these stability assays was 
solved in our laboratory, our collaborators at MRCT used the atomic coordinates of 
the nucleotide-binding sites of AMPK in a virtual screen to identify potential 
ligands. More than 2 million compounds were analyzed in the virtual screen and this 
resulted in a good drug docking-site score for 413 compounds. The compounds thus 
identified from the virtual screen were bought in to be assessed with our thermal 
stability assay. To minimize experimental time and the amount of the protein used, 
compounds were screened in pools of four. The concentration of each of the four 
compounds in the assay was 50 μM. Because the compounds were dissolved in 
100% DMSO the control was an AMPK sample with the same final DMSO 
concentration. When a mixture of four compounds gave a Tm shift of >1˚C relative 
to the control each of the four compounds was assayed individually. 
  
Among these 413 compounds I discovered one (C05-1) that produced a significant 
shift in the unfolding curve to a higher temperature. 50 μM of this compound give a 
Tm value of 56.7˚C, which is significantly above the average Tm of the other 
compounds [53.2 (± 0.3)˚C] (Fig 4.21). This ligand is more effective in stabilizing 
AMPK than AMP as concentrations as low as 50 μM gives a Tm shift comparable to 
that produced by ~ 210 µM AMP, meaning that C05-1 could be binding stronger 
than AXPs. However, this compound does not appear to bind in the exchangeable 
binding sites, as monitored by fluorescence binding assays (section 4.2.7). Also, our 
collaborators tested whether C05-1 mimics the effects of AMP (i.e. allosteric 
activation and reduced dephosphorylation) but neither of the two effects was 
detected (Matt Sanders, personal communication). In conclusion, the novel C05-1 
compound is going to be employed for co-crystallization trials with the full-length 
protein, for which no structure is yet available. Hopefully the stabilizing properties 
of the compound will facilitate crystallization trials.    118
 
Figure 4.21: Structure and effect of C05-1. (a) Chemical structure of C05-1. (b) 
Thermal shift assay results for AMPK in the absence, and presence of tested 
compounds. The control curve is in black. Compound concentration is 50 μM. The 
green line represents an average curve for the 412 non-binding compounds. The 
53.2˚C Tm value for this curve does not differ significantly from that of the control 
(53.1˚C). C05-1 compound (red) instead seems to stabilize the protein and causes a 
positive shift of 3.5˚C. 
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5. Discussion  
5.1 Overview 
The aim of my thesis was to characterize, through structural and binding studies, the 
mechanism of regulatory nucleotide binding to mammalian AMPK. The crystal 
structure of truncated AMPK shows how the heterotrimeric complex is formed and 
that there are three nucleotides binding sites on the γ regulatory subunit. I used 
mant-AMP as a fluorescent reporter to determine, by competition experiments, the 
affinity of AMP & ATP for the two exchangeable ones. HPLC experiments explained 
the observation of three bound AMPs in the crystal structure because the third site is 
non-exchangeable. Crystal soaking experiments with ATP helped to assign site-1 & 
site-2 as the exchangeable binding sites and site-3 as the non-exchangeable AMP 
site. Interestingly, I also discovered that NADH and NADPH bind to one of the two 
exchangeable sites. Given its intrinsic fluorescent properties I used it as a reporter 
for further binding studies.  
 
The reason why a pseudo-symmetric ‘fourth site’ in γ remains empty in mammalian 
AMPK is discussed and compared to the structure of a yeast homologue of AMPK, 
SNF-like protein. I carried out further structural and binding studies on AMPK with 
the activator ZMP to better understand why it binds with reduced affinity to AMPK, 
and thus its poor potency compared to physiological ligands such as AMP. Crystal 
structures and binding affinities for nucleotides were determined for three naturally 
occurring AMPK mutants. Arg-69ÆGln, His-150ÆArg and Arg-298ÆGly, 
represent three of the most common mutations that appear in Wolff-Parkinson-White 
syndrome. I suggest that the phenotype of this disease arises because the binding of 
nucleotides to site-2 is diminished.  
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5.2 The AMP binding site 
The ability of AMPK to monitor cellular energy status comes from its capacity to 
competitively bind adenyl-containing nucleotides (AXPs) at its regulatory γ subunit 
16. The γ subunit of AMPK is made up of two Bateman domains, each being 
composed of a pair of CBS motifs 
16-17. A CBS motif is a conserved domain of about 
60 amino acids. The crystal structure of truncated AMPK shows how each one of the 
four CBS motifs consists of a conserved α1-β2-β3-α4 pattern in an anti-parallel 
arrangement 
213 (Fig 5.1). The packing of these four pseudo-symmetric motifs 
generates four potential adenyl binding sites. Interestingly, in the truncated wild type 
AMPK structure only three of these sites are seen to bind AXPs bind. One 
nucleotide binds between CBS 1-2 (site-1) and two nucleotides between CBS 3-4 
(site-2 and site-3) (Fig 5.1). Each of the three nucleotides sits in a partially basic 
pocket formed at the interface between a pair of CBS domains (Fig 5.2 A&B). 
Between CBS 1-2 there is a potential fourth nucleotide binding site, but in 
mammalian AMPK no nucleotide has been observed at this site (discussed in more 
detail in section 5.6). 
                                           CBS-4                               CBS-3 
 
 
Figure 5.1: Ribbon representation of AMPK in complex with three AMP molecules. 
A face-on view of Bateman 1 is shown. CBS 1-2 (Bateman 1) are colored in red and 
orange, whereas CBS 3-4 (Bateman 2) are in yellow and magenta, respectively. 
CBS-1 
CBS-2 
     122
 
   
Figure 5.2: Surface representation of AMPK in complex with three AMP molecules. 
(A) Face-on view with site-1 and site-3; (B) View after rotating the molecule 180˚ 
around vertical axis showing site-2. The surface is colored according to the 
electrostatic potential [blue, positive (contour level +30.0 KbT / ec); red, negative 
(-30.0 KbT / ec)]. AMP molecules are in stick representation with carbon atoms in 
yellow. 
 
 
 
Bateman domains occur in over a thousand other known proteins such as metabolic 
enzymes, kinases, and membrane channels and are responsible, in some of these 
cases, for binding adenosine-containing ligands such as AMP, ATP or SAM 
between a pair of CBS motifs 
16,21. What makes AMPK apparently unique is that 
although AXPs bind at the interface of two CBS motifs within a Bateman domain, 
there are additional interactions of the nucleotides with amino acids from the distal 
Bateman domain; for example, AMP-2 interacts with residues predominantly from 
CBS3-4, but also with Arg-69 and Lys-169 (which belong to CBS-1 and -2, 
respectively); AMP-3 interacts with residues from CBS3-4 but also with His150 
(CBS-2) (Fig 5.3).  
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Figure 5.3: Ribbon representation of AMPK in complex with three AMP molecules. 
CBS 1-2 (Bateman 1) are colored in red and orange, whereas CBS 3-4 (Bateman 2) 
are in yellow and magenta, respectively. AMP molecules are in stick representation 
with carbon atoms in green.  
 
 
 
5.3 Characterizing the three binding sites 
Binding studies using a fluorescent-labelled analogue of AMP, mant-AMP, gave a 
stoichiometry of 2:1 (nucleotide/protein). The finding that the crystal structure 
contains three bound AMP molecules is rationalized by bound-nucleotide studies 
which show that AMPK contains one permanently bound AMP moiety (see section 
4.1). Competition assays, using mant-AMP as a reporter, demonstrate that AMP, 
ADP and ATP can all bind at the two exchangeable nucleotide binding sites. 
 
Initially, I assumed that both exchangeable sites had equal affinities, but with more 
experiments and re-examination of the original data I realized that the two 
exchangeable sites have significantly different affinities for nucleotides. I was able 
to determine the affinity of mant-AMP and AXPs for the stronger of the two sites 
R69 
K169 
H150 
AMP-2 
AMP-3
AMP-1 
CBS-1 
CBS-2 
CBS-3 
CBS-4   124
reasonably accurately, but somewhat less so for the weaker site. This is explained in 
more detail in section 4.2.3 but, in brief, in a system where a fluorescent reporter 
binds to two sites with different affinities, the consequent fluorescent signal is 
mainly due to the contribution from the high affinity site and less information can be 
extracted for the weaker site. The Kd of AMP and ATP for the tight site of wild type 
AMPK are in the range 1-3 μM. In contrast, the affinities of AMP and ATP at the 
weaker site are in the range of 20-40 μM and 40-70 μM, respectively. The difference 
in affinities between the two sites suggests that it is likely that the tight site is 
responsible for the enzyme’s sensitivity to cellular AMP changes and therefore 
important for regulating kinase activity. 
 
 
The complementary use of structural and binding studies enabled the identification 
of the non-exchangeable site and the likely assignment of the tight and weak 
exchangeable sites. Crystal soaking experiments using either ATP, or ZMP, suggest 
that site-3 is non-exchangeable whereas site-1 & -2 can bind nucleotides other than 
AMP (Fig 5.4). Although not a quantitative measure of binding affinity, site-1 
consistently shows stronger electron density for bound nucleotide ligands than 
site-2. One has to be very cautious when correlating occupancy of binding sites in a 
crystal with binding affinities in solution, but the best guess would be that site-1 is 
the tight site and site-2 the weak site. Additional reasons for these assignments are 
discussed in section 5.8. 
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Figure 5.4: Ribbon representation of the crystallized complex with three bound 
AMPs in two orthogonal views. The α, β and γ subunits are colored in cyan, green 
and red, respectively. 
 
 
5.3.1 Specificity of mant-AMP for AMPK 
The availability of fluorescent-labelled nucleotides opens up a very useful way of 
measuring binding of unlabelled nucleotides by competition experiments. However, 
the generation of fluorescently labelled nucleotides often involves the introduction 
of an additional hydrophobic group. This new substituent may lead to additional, 
adventitious, interactions with the protein that do not occur with unlabelled 
nucleotides. For example, the julolidine derivative of ATP shows an increase in 
fluorescence signal upon addition to myosin subfragment-1, but this effect is not 
reversed upon addition of ATP, indicating that it binds to sites other than the active 
site 
221. Mant-nucleotides have been shown to bind specifically to proteins such as 
ATPases and GTPases 
221. However, mant-AMP has not previously been used in the 
study of nucleotide binding to AMPK.  
 
In order to confirm, and visualize, how mant-AMP binds at the exchangeable 
nucleotide binding sites of AMPK, I solved the crystal structure of AMPK in 
complex with mant-AMP by soaking crystals with 0.5 mM mant-AMP overnight. 
The structure shows mant-AMP moieties bound at site-1 & site-2, while the third 
non-exchangeable site remains occupied by AMP (Fig 3.9A). In the AMPK/AMP  
AMP-3 
non-ex 
AMP-1 
AMP-2 
AMP-1 
AMP-2 
AMP-3 
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complex, the ribose of AMPs makes a bidentate interaction between the 2’ and 3’ 
hydroxyl groups of the nucleotide with the negatively charged side chain of an 
aspartate residue. In the AMPK/mant-AMP complex, the mant-group, which is 
linked via the ribose, does not significantly alter the binding of the adenyl moiety 
even though one of the hydrogen bonds between the aspartate and the ribose is lost 
(Fig 5.5). The mant moiety extends away from the adenyl binding pocket onto the 
surface of γ. In site-1, the mant group hydrogen bonds with the side chain of Asn-92 
and makes hydrophobic contacts with Tyr-120, Leu-121, Gln-122 and Lys-126. In 
site-2, the mant moiety makes hydrophobic interactions with Phe-243, Arg-268, 
Ser-269, His-270 and Tyr-271 (Fig 5.5) (see details in 3.2.4). 
 
 
Figure 5.5: Atomic model of mant moiety. The binding pocket shown is site-1. 
Carbon atoms of AMPK and of the mant-AMP are in grey and yellow sticks, 
respectively. 
 
 
5.4 Cooperativity 
Cooperativity refers to the enhanced binding of a ligand to a protein due to the prior 
binding of the same ligand at another site. The best known example of a multimer 
displaying cooperative binding is the binding of four oxygen molecules to 
Asn-92 
Tyr-120 
Leu-121 
Gln-122 
Lys-126   127
haemoglobin. It is composed of four separate globin chains (α2β2), each capable of 
carrying one molecule of oxygen. On the other hand, an example of proven 
cooperativity within a single polypeptide chain is calmodulin. The crystal structure 
of calmodulin resembles a dumbbell with two globular domains separated by a 
central helix and each one of these domains contains two Ca
2+-binding sites 
234. 
Positive cooperativity for calcium binding to calmodulin takes place within each 
globular domain, whereas cooperativity is not observed between the globular 
domains.  
 
The cooperativity factor, α, is commonly used as a measure of the cooperativity 
displayed by a system. If α  > 1 there is positive co-operativity between ligands 
binding at different sites; if α < 1 then there is negative co-operativity. The value of 
α depends on the free energy change for binding at a site when the other is occupied. 
α can only be properly calculated in cases where one has two identical sites, which is 
unlikely to be the case in systems other than those containing multiple subunits, e.g. 
haemoglobin. The Hill equation is also used as a measure of cooperativity in systems 
in where multiple ligand molecules bind to a protein. The Hill equation provides a 
useful means of assessing cooperativity but it has clear limitations. For example, the 
equation can provide evidence for positive cooperativity; however, it can not be used 
to definitely show negative cooperativity or non-cooperative binding without also 
knowing the relative affinities of the different sites on the protein for the ligand. In 
addition, the Hill equation can not provide accurate measurements of the Kd values 
for the interaction of a nucleotide at any site on the protein, or a quantitative 
assessment of the level of cooperativity (i.e. it is not obvious how to convert the Hill 
constant to α). The Hill equation can be useful for determining whether there is 
positive cooperativity in systems where two or more molecules of one type bind to a 
single target. The limitations in the Hill equation analysis result from the primary 
assumption that intermediate complexes with AXP bound only to one site do not 
exist. Clearly, this is not the case for AMPK. 
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A previous study by Scott et al 
16 has suggested that AMP binding to AMPK is 
cooperative. In my binding studies, the data can readily be fitted assuming that there 
is no cooperativity between the two exchangeable sites. The difference in 
interpretation between my work and that described previously could be due to the 
use of significantly different constructs. Scott et al. used a full-length γ subunit, or 
part of it, with a GST tag. My construct does not have a GST-tag but is a complex of 
the three subunits. The hydrophobic interaction between the carboxyl terminal of the 
β subunit and the γ subunit seems to be important for the stable association of the 
subunits and the ability of the complex to remain monodisperse. However, to 
investigate the potential impact of cooperativity on AMP binding to AMPK, a 
cooperativity parameter was added to the fitting equation I used. A simulation of this 
binding model is shown graphically in Fig 5.6 and in Table 5.1. 
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Figure 5.6: (A) Schematic representation of two nucleotides binding to AMPK: 
where K = kinase; A = AMP; In (B), Kd(I) and Kd(II) (affinity of AMP for site I & II) 
are simulated to be 1 μM & 5 μM, respectively; the fluorescence derived from site I 
& II is identical (F(I)=F(II) therefore F(I)/F(II) =1 and F(I, II)= F(I)+F(II)). The black line is 
the best fit for a 2:1 non-cooperative complex (α =1). Two other lines (green & blue) 
represent the fit for a cooperative complex (α =0.5 & α =5, respectively) and are 
completely overlapping. The residual plot demonstrate that the curves with or 
without including an α term fit just as well, although the Kd values change (Table 
5.1). 
A  B   129
 
1.16 3.1 0.73 1 0.5
1.07 11.2 1.18 1 2
1.12 1.5 1.15 0.4 1
1.09 32.5 0.81 5.0 1
1.09 5.7 0.91 1 1
χ2 Kd/(II) (μM) Kd/(I) (μM) α F(II)/F(I)
1.16 3.1 0.73 1 0.5
1.07 11.2 1.18 1 2
1.12 1.5 1.15 0.4 1
1.09 32.5 0.81 5.0 1
1.09 5.7 0.91 1 1
χ2 Kd/(II) (μM) Kd/(I) (μM) α F(II)/F(I)
 
Table 5.1: Insertion of cooperativity as an additional fitting parameter: if α = 5 then 
the affinity of AMP for site I & II become respectively 0.8 μM and 32.5 μM; if α = 
0.4 (negative cooperativity) then the affinity of AMP for site I & II become 
respectively 1.1 μM and 1.5 μM. In fits where a new parameter is added, the chi
2 (χ
2) 
should change if the term is meaningful. In simulations both with and without a 
cooperativity factor the chi
2 remains unchanged suggesting that there is no 
mathematical justification to adding this term as an additional parameter in the 
fitting equation. 
 
What the simulations demonstrate is that the only effect of including a positive 
cooperativity term is to make the binding constant for the weaker site lower than it 
otherwise appears. It does not improve the quality of the fit. As far as I can 
understand, my interpretations of AMPK regulation do not change whether I assume 
a weak-binding second site or a very weak binding second site that becomes tighter 
upon prior occupation of the tighter site. 
 
Cooperativity can only be properly determined in a binding assay where the degree 
of saturation ([bound ligand]/[total protein] can be determined as a function of free 
ligand concentration 
234. This can be done with techniques such as equilibrium 
dialysis or by radioactive-labelled nucleotides in a filter-based binding assay 
235. I 
did not have the facility to handle radioactive-labelled nucleotides and so I did not 
investigate this issue 
16. It is not easy to understand structurally, in the case of 
AMPK, how the addition of a negative charge from the phosphate of a nucleotide 
can help the binding of another negatively charged phosphate relatively close by. In   130
the final analysis my studies do not disprove positive cooperativity, but my data can 
be fit perfectly well without it. 
 
5.5 Potential role of NAD(P)H as a down-regulator of AMPK 
The non-equivalence of the two exchangeable binding sites is also evident from the 
fact that NAD(P)H binds to one of them but not the other. NADH/NAD
+ and 
NADPH/NADP
+ are essential cofactors in a range of biological processes, including 
the regulation of cellular energy metabolism 
236. None of these species have been 
considered to be involved in AMPK regulation as they do not allosterically activate 
the enzyme. However, my fluorescent titrations show that NADPH has an affinity of 
about 19 μM for AMPK, whereas the oxidized form, NADP
+, binds much weaker 
with a Kd of over 1 mM. My experiments show that both NADPH and NADH 
compete with AMP, ADP and ATP for binding to one of the two exchangeable sites 
on AMPK. Competition experiments with NADPH suggest Kd values around 1-
3 µM for AXPs, in good agreement with the data obtained for the tighter of the two 
sites by mant-AMP. The fact that NADPH monitors AXPs binding at low 
micromolar affinity suggests that the cofactor binds to the higher affinity 
exchangeable site. As mentioned above (section 5.3), in the context of the truncated 
construct, I cautiously attribute the higher affinity binding to site-1 (Fig 5.7).  
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Figure 5.7: Schematic representation of the binding mode of NADPH and 
mant-AMP. NADPH binds to the tighter of the two exchangeable sites whereas 
mant-AMP binds to both. 
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In order to confirm that NADPH binds at site-1 of AMPK I carried out a series of 
soaking and co-crystallization experiments. Co-crystallization trials were 
unsuccessful as the resulting 2.6Å structure resulted in a map with poor density near 
the nucleotide binding sites that could not be interpreted. It is possible that the 
cofactor oxidized during the course of my crystal soaking experiments. However, 
from very recent crystallization work carried out in the lab by other workers, it 
seems that one NADH molecule binds to site-1 of the truncated mammalian AMPK 
construct (Richard Heath, personal communication). While I am disappointed 
that I did not achieve this result, it is gratifying to see that it supports my general 
conclusions.  
 
This NADH/AMPK complex also offers a molecular explanation of why the protein 
binds the reduced, but not oxidized, forms. The nicotine group of NADH interacts 
with four basic residues (Arg-69, Lys-169, His-297 and Arg-298) (Richard Heath, 
personal communication), suggesting that there would be considerable electrostatic 
repulsion with the positively charged oxidized form of the cofactor. 
 
As well as ATP, NADPH and NADH represent biochemical energy reserves. The 
large difference in affinity between the reduced and oxidized form of NADPH and 
NADH suggests that the binding of these nucleotides could be physiologically 
relevant. I propose that NADPH and NADH, like ATP, are physiological 
competitors for AMP binding to AMPK, and act to down-regulate AMPK by 
reducing its allosteric activation and its phosphorylation level. Therefore in the cell, 
in homeostasis, AMPK is mostly bound to ATP, NADPH or NADH, competing out 
AMP binding to the two exchangeable sites (Fig 5.8). Under these conditions the 
enzyme is more likely to be de-phosphorylated. When the cell is subject to metabolic 
stress, ATP is converted into ADP & AMP and NADPH and NADH are oxidized to 
NADP
+ and NAD
+. Thus, a higher proportion of the enzyme will be bound to AMP 
and in turn it will be more active. Thus, my suggestion is that AMPK may be 
down-regulated by ATP, NADH or NADPH but up-regulated by AMP.   132
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Figure 5.8: Diagram representing AMPK during energy homeostasis and during 
cellular stress. In homeostasis AMP levels are low; therefore AMPK is in the 
ATP-bound or NAD(P)H-bound state. In this state AMPK is kept de-phosphorylated 
by phosphatases (PP2C/PPM) and is therefore largely inactive. Cellular stress 
increase AMP concentration which competes off ATP and NAD(P)H binding to the 
γ subunit of AMPK. When upstream kinases (LKB1 and CaMKKβ) phosphorylate 
AMPK at Thr 172, AMP protects the activation loop from dephosphorylation and 
AMPK retains more activity.  
 
 
5.6 The empty ‘fourth’ site 
The approximate symmetry relating the four CBS motifs of AMPK generates four 
basic pockets. In mammalian AMPK, three of these pockets are occupied by 
nucleotides, whereas the fourth remains empty. The crystal structure of the AMPK 
homologue from S. Pombe, suggest that site-3 can bind either AMP or ATP (PDB 
coords: 200X, 200Y; 
113). A later publication by the same group involved soaking 
ADP into these crystals which then showed ADP bound in site-4 and either AMP or 
ATP in site-3 (2QRC; 2QRD 
237). Inspection of the mammalian AMPK structure 
suggests that nucleotides do not bind at site-4 because there is no aspartate from the 
γ subunit  which can form a bi-dentate hydrogen bond with the 2’ and 3’ hydroxyl 
groups of the ribose (as there is for the other three sites). Interestingly, in the 
SNF-like protein, an aspartate from the β subunit, Asp-250, interacts with the ribose   133
of ADP-4. This aspartate residue is conserved across species and is the equivalent of 
Asp-226 in the β subunit of the mammalian structure (Fig 5.9A). The super-position 
of the two structures suggests that nucleotides could, theoretically, bind in site-4 of 
mammalian AMPK (Fig 5.9B & 5.10). However, in our AMPK structure, the loop 
from β-223 to β-232 is disordered in all the complexes we have looked at. Moreover, 
my binding studies on AMPK always show two, and not three, exchangeable sites. 
Since I do not have access to detailed binding data for SNF-like protein, it is difficult 
to know whether this ‘fourth’ site is really occupied in solution or if it is the result of 
soaking a crystal in very high concentrations of ligand. 
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Figure 5.9: (A) Sequence alignment (Clustlax) of a fragment of β subunit of 
mammalian AMPK with SNF-like protein (S. Pombe) which, in yeast, appears to 
interact with nucleotides at site-4. (B) Superposition of mammalian AMPK with 
SNF-like protein. The γ subunits of AMPK and SNF-like are in green and pink, 
respectively. The β subunit of AMPK is in orange with the two edges of the missing 
loops in red. The β subunit of SNF-like is in cyan with the equivalent loop in blue. 
The ADP is in sticks with carbon atoms in yellow.  
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Figure 5.10: ADP-4 site: Superposition of mammalian AMPK with SNF-like 
protein. In the yeast structure, ADP binding is apparently facilitated by the hydrogen 
bonding between the 2’ and 3’ hydroxyl groups of the ribose with Asp-250 and the 
4’ oxygen of the ribose and the amino group of the side chain of Gln-251 in β. In the 
adenosine part, the NH2 at position 6 hydrogen bonds with carbonyl group of the 
main chain of Ser-57 and Ile-35 (the corresponding residues in mammalian AMPK 
are in parenthesis: Ala-70, Val-48). The N1 atom interacts with amino group of the 
main chain of Ile-35. The α phosphate of ADP interacts with Val-56 (Arg-69), 
Arg-142 (Arg-151), Arg-287 (Glu-295); the β phosphate with Thr-162 (Thr-167), 
Tyr-164 (Lys-169), Arg-165 (Arg-170) and His-289 (His-297). Proteins and the 
ADP are in sticks representation. The γ subunits of AMPK and SNF-like are in 
green and pink, respectively. The extra loop from the β subunit of SNF-like is in 
blue sticks. The ADP is colored with carbon atoms in yellow. Residues from 
SNF-like protein have been labelled. 
R165 
R287 
O3’ O2’  O4’ 
Q251 
N6 
N1 
I 35 
D250 
V56 
R142 
T162 
H289 
Y164   135
 
Interestingly, in the crystal structure of SNF1, the AMPK homologue in S. 
Cerevisiae 
112, no nucleotide has been reported in any of the four potential binding 
sites, although the crystals were grown in the presence of 1 mM AMP. By 
fluorescence binding assays I was able to show that one AXP nucleotide binds to 
SNF1. Crystal soaking experiments with SNF1 recently enabled a member of our lab 
to solve the crystal structure of SNF1 in the presence of AMP in site-3 (Richard 
Heath, personal communication). Thus, nucleotides bind to the S. Cerevisiae 
homologues of AMPKs in site-3 which corresponds to the non-exchangeable site of 
mammalian AMPK. This single site binding is in agreement with my binding studies 
on SNF1.  
 
 
 
 
5.7 Binding of ZMP to AMPK 
AICAR is metabolized to ZMP within cells by phosphorylation at the 5′ position. 
Since, to some extent, it mimics the effects of AMP on AMPK, it has been widely 
used as an activator in AMPK biochemical studies. Unfortunately, its potency is 
significantly less than for AMP 
59,90. I determined that the affinity of ZMP for the 
tight exchangeable site of AMPK is about 18 μM and over a hundred micromolar for 
the weak site (see section 4.2.7). The crystal structure of a fragment of the γ-domain 
of mammalian AMPK in complex with ZMP has previously been reported 
238. In 
that case the construct comprised just one Bateman domain (CBS3-4) and the single 
ZMP was bound at a site that corresponds to our non-exchangeable AMP-3 site. 
Although the crystal soaking experiments reported with the γ fragment construct 
involved incubating crystals for 1-2 days with 20 mM ZMP, neither an AMP nor 
ZMP were seen in the AMP-2 site. My structural and binding studies lead me to 
speculate that the AMP-2 site is the weaker of the two exchangeable AXP sites on 
AMPK (see section 5.3). I used X-ray crystallography to understand the structural 
basis for the poorer binding and potency of ZMP relative to AMP. The 2.1 Å 
resolution electron density map shows that, in my construct, 2mM ZMP leads to   136
good occupancy at both the exchangeable sites (corresponding to AMP-1 and 
AMP-2 sites of the AMPK/AMP complex [Fig 3.6B]). The presence of ZMP in 
site-1 and -2 in my construct, but not in the truncated γ construct, probably occurs 
because nucleotide binding involves additional interactions of the nucleotides with 
residues from the other Bateman domains.  
 
ZMP-1 adopts a very similar binding mode to the corresponding nucleotide in the 
AMP complex. In contrast, ZMP-2 does not superimpose that well with the 
corresponding AMP-2 of the wild type structure (Fig 3.8A). Binding of ZMP-2 to 
AMPK, in my construct, involves a conformational change in the side chain of 
His 297 relative to the AMP-bound enzyme. In its new orientation, the side chain of 
the histidine is oriented away from AMP-3 and interacts with ZMP-2. The 
re-oriented His-297 does not clash with the α phosphate of ZMP-2, as I see with 
WPW mutants, because of the change in conformation of the nucleotide just 
mentioned (section 5.8).  
 
Additionally, the structure suggests that ZMP-2 binds weakly because of the loss of 
interaction between the phosphate group of the nucleotide and the side chain of a 
couple of basic residues from the protein (section 3.2.3). This probably accounts for 
the reduced potency of this drug. 
 
Adenosine-like nucleotides activate AMPK, whereas other nucleotide 
monophosphates such as GMP, CMP, IMP, UMP and 6-SH-PMP (6-mercaptopurine 
riboside 5’-monophosphate) do not 
90,239. All these compounds have a similar 
monophosphate riboside moiety but they differ in the nucleobase (adenosine, 
cytidine, guanine, thymine, uracil and 6-mercaptopurine riboside) (Fig 5.11). 
Interestingly, compounds like ZMP, tubercidin 5’-monophosphate (Tu-MP) and 
5’-deoxy-AMP (dAMP) (Fig 5.11) do activate AMPK, thus leading Henin et al. to 
suggest that a free 6-NH2 group in the nucleobase may be critical for ligand binding 
to γ. My crystal structure shows how ZMP mimics AMP binding by retaining the 
hydrogen bonds between the free-NH2 atom at position N2 and two main chain   137
carbonyl groups from the protein, and thus confirms this earlier suggestion (Fig 
3.8B) 
90. 
 
       
            AICAR                              Adenosine              Guanosine 
   
                   Cytidine                         Uridine                        Inosine                  
   
6-mercaptopurine riboside             Tu-MP     deoxy-adenosine 
Figure 5.11: Comparison of the structures of AICAR with other nucleosides. When 
AICAR is phosphorylated it becomes ZMP. In this figure, selected atoms 
positioning of AICAR and adenosine are numbered in red.  
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5.8 WPW structures and implications for AMPK activation 
Naturally occurring mutations in mainly basic residues of the γ2 isoform of AMPK 
cause WPW syndrome, which is a glycogen storage cardiomyopathy associated with 
electro-physiological abnormalities. Mapping of the corresponding residues onto the 
γ1 component of the crystal structure shows that most of the mutations involve the 
side chains of amino acids found close to the nucleotide binding sites 
213. I looked at 
three of the most common mutations involving Arg-69, His-150 and Arg-298. 
Arg-298 and Arg-69 interact with nucleotide in binding site-2, whereas His-150 
interacts with the non-exchangeable AMP-3 and with the AXP in site-1 (Fig 5.12).  
 
    
Figure 5.12: Surface representation of wild type AMPK. The front view (left) shows 
site-1 & site-3 and the back view (right) shows site-2. Residues His-150 (green), 
Arg-69 (blue) and Arg-298 (red) are shown in stick representation, AMP molecules 
are also in stick representation with carbon atoms colored in yellow.  
 
To study the role of these three mutations, I made the relevant constructs, expressed 
and purified the proteins, and carried out binding and structural studies. Using 
NADPH competition I determined that wild type AMPK binds AMP, ADP and ATP 
at 3.3 µM, 1.3 µM and 1.1 µM at the tighter site. Interestingly, the three mutants 
Arg-69Æ Gln, His-150ÆArg and Arg-298ÆGly show similar values for this tighter 
non-ex 
site-3 
site-1 
site-2 
empty 
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site (section 4.2.5). Consistent with these results, the competition of mant-AMP with 
AXPs appears largely unchanged at the tighter site but is reduced to different 
extents, at the weak site. Arg-69ÆGln is reduced about two-fold while 
His-150ÆArg and Arg-298ÆGly are down about 8-fold and 11-fold, respectively.  
 
To test whether the non-exchangeable site-3 is conserved in the Arg-69ÆGln, 
His-150ÆArg and Arg-298ÆGly mutants, I examined the over-expressed and 
purified mutant proteins by high-performance liquid-chromatography for bound 
nucleotides. All three mutant protein samples showed approximately one AMP 
molecule bound for every AMPK. Interestingly, when His-150, which interacts with 
the non-exchangeable AMP, is mutated, the resulting protein still co-purifies with 
one AMP moiety (Fig 4.1). These results indicate that WPW mutations affect only 
the binding at the weaker site of the two exchangeable sites.  
 
I also used X-ray crystallography to examine nucleotide binding to these three WPW 
mutants. Crystals of the mutant proteins in complex with AXPs diffracted to 
reasonably high resolution (2.0 Å to 2.6 Å) and produced clearly defined electron 
density for bound AMP in site-1 and the non-exchangeable site-3. There was no 
electron density for nucleotides in site-2 in either His-150ÆArg or Arg-298ÆGly, 
but there was for the Arg-69ÆGln mutant. This result is consistent with 
Arg-69ÆGln being the mutant that is least affected in the binding studies, with only 
a two-fold decrease in affinity for nucleotides in the weak site compared to wild type 
AMPK.  
 
The situation was somewhat different when I carried out ADP and ATP soaks on 
these crystals. Interestingly, in the R298G/ATP complex there is some electron 
density for nucleotide in site-2. I was able to model ATP into this site and refine it 
with an occupancy of 0.5 which indicates that ATP binding to site-2, at least in the 
crystal, is more favorable than for AMP or ADP. This data is consistent with the 
fluorescence binding experiments on WPW mutants described in section 4.2.5, 
where mant-AMP is more strongly displaced in the weak site by ATP than AMP   140
(Fig 4.14B). This suggests that in WPW mutants, site-2 preferentially binds ATP 
rather than AMP. These observations may explain why kinase activation in WPW 
proteins is compromised. A weaker affinity for AMP, and with unchanged Kd for 
ATP, would lead, presumably, to a less active, and less activatable enzyme. 
 
As stated above, the overall structure of the WPW mutant proteins is similar to wild 
type. The main differences occur in the occupancies of nucleotides in the weaker of 
the two exchangeable sites and in the rearrangement of the side chain of residue 
His-297. The side chain of this residue is rotated 120º about the Cα-Cβ bond in the 
His-150ÆArg and the Arg-298ÆGly structures (Fig 5.13). In the wild type structure 
the imidazole group of the histidine hydrogen bonds or salt bridges with the 
phosphate of AMP-3; in the His-150ÆArg and Arg-298ÆGly mutants, the new 
orientation of the side chain of the histidine would clash with the α phosphate of 
AMPs in site-2 - if it were occupied. This could account for the reduced affinity of 
one of the two exchangeable AMP sites. It is possible that ATP binding to site-2 is 
less affected because of the extra interactions of the γ phosphate of the ATP with the 
side chains of Arg 151, an interaction which is not possible when either AMP or 
ADP are bound. This interpretation is consistent with the Arg-298ÆGly structure in 
complex with ATP which displays partial occupancy for ATP in site-2. 
 
The complementary use of binding and structural studies with WPW mutants 
consistently show that site-1 remains unchanged, confirming the suggestion (see 
section 5.3) that, at least in the construct I am working with, site-1 is the tight site 
and site-2 is the weaker site. 
 
   141
 
 
Figure 5.13: Ribbon representation of the superposition between wild type and 
mutant mammalian AMPK structures: wild type protein is in cyan and the WPW 
mutant Arg298ÆGly is in purple. AMP molecules are shown in stick representation 
together with selected residues important in nucleotide binding. 
 
  
Yeast AMPKs (SNF1 in S. Cerevisiae and SNF-like protein in S. Pombe) are not 
regulated by AMP as far as I am aware. Interestingly, if I overlap my AMPK 
structure with the two yeasts structures (SNF1 
112 and SNF-like protein 
113) the 
position of the side chain of the histidine (corresponding to mammalian AMPK 
His-297) is different. In yeast AMPKs, the rotamer adopted by the histidine is 
similar to the one selected by WPW mutants in mammalian AMPK. These two yeast 
structures do not have nucleotides bound at site-2, possibly because the α phosphate 
of the nucleotide in site-2 clashes with His 297 in the same way seen with the 
mammalian WPW mutants. As a consequence I speculate that the affinity for AMP 
in site-2 of yeast AMPKs is too weak to be measured or to be physiologically 
relevant (Fig 5.14).  
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Figure 5.14: Ribbon representation of the superposition between wild type AMPK 
and yeast homologues: AMPK is in cyan, SNF1 in Violet and SNF-like is in orange. 
AMP molecules are from the AMPK complex only. AMP molecules with carbon 
atoms in grey are shown in stick representation together with residues important in 
nucleotide binding. 
 
 
5.9 Concluding remarks 
AMPK functions as a master regulator of cellular energy metabolism. The aim of 
this thesis was to understand, via structural and binding studies, the regulation of 
AMPK by nucleotides which may help the design of sensitive and potent activators 
of this protein kinase. My work on AMPK demonstrates that the two exchangeable 
nucleotide binding sites have different affinities. It is likely that the tighter of the 
two is the site important in mediating allosteric activation and the protection from 
dephosphorylation of the kinase domain. 
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The affinity of nucleotides for site-2 is difficult to establish accurately, but finding a 
specific fluorescent reporter for site-2 might help determining the Kd of ligands for 
this site. We are still missing the crystal structure of full-length protein showing the 
GBD and the kinase domain interacting with the rest of the protein and such a 
structure is probably necessary to further enhance our understanding of the 
regulation of the kinase. Much work still needs to be done in order to elucidate the 
molecular mechanisms of AMPK. Given the tempo of discoveries in this field it may 
well be that we will not have to wait too long before such data are available. These 
may well inform the development of new drugs and AMPK activators as promising 
leads for the treatment of disorders such as the metabolic disorder, obesity, diabetes 
and perhaps some forms of cancer 
129.  
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Epilogue 
 
After submission of my thesis, several additional pieces of work were finished in the 
lab which gives additional confidence to the interpretation of my data. Firstly, as I 
have described, the binding of NADH to AMPK occurs at the tighter of the two 
exchangeable sites. Recent work from Carling’s lab has shown that NADH, even at 
high concentrations, does not compete with AMP for protection against 
de-phosphorylation. Secondly, also from Carling’s lab, the dose response of the 
protection from de-phosphorylation by AMP also correlates closely with binding at 
the weaker, but not the stronger of the two exchangeable sites. Finally, recently 
completed work in the Gamblin lab has revealed the crystal structure of an active 
AMPK complex (Bing Xiao, personal communication). One of the notable 
features of this structure is that a part of the α chain, that links the kinase domain to 
the regulatory fragment, is ordered and interacts with the AMP-2 binding site. Taken 
together, these data argue strongly that it is AMP binding at the weaker of the two 
exchangeable sites that is responsible for mediating protection against 
de-phosphorylation. 
 
If AMP binding at site-2 is the site that is important for protection against 
de-phosphorylation, the reduced affinity of AMP for site-2 would explain the 
reduced levels of AMPK activity seen in WPW mutants. Sanders et al. have shown 
that the effect of AMP on protection of AMPK against de-phosphorylation is lost in 
the Arg298ÆGly mutant and reduced in the His150ÆArg and the Arg69ÆGln 
mutants [10]. In this light, my results on WPW mutants, both in solution, and by 
crystallography make good sense. I find that these mutations reduce the affinity for 
nucleotide binding to site-2 – the weak site. Therefore, my conclusion is that WPW 
mutants exert their effect because they alter nucleotide binding at the weaker 
exchangeable site and this results in reduced protection against de-phosphorylation 
thus leading to lower enzyme activity.  
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Appendix 1: Analysis of fluorescence binding studies 
1.1 Titration of mant-nucleotide or NADPH with AMPK 
The Kd values of the titration assays where determined according to the following 
model: Assuming that there are two similar and separate AXP binding sites and that 
each one does not necessarily produce the same fluorescent signal at the binding of 
the labeled nucleotide, the nucleotides mant-AXP or NADPH (N) bind to 
AMP-Kinase (K) according to the following scheme: 
N + K ↔ NK with Kd  =  ([N][K])/[NK]      (1) 
Total concentrations of AMPK and nucleotide (KT and NT) are given by:  
KT  =   [ K ]   +   [ N K ]          ( 2 )  
MT  =  [N]  +  [NK]         (3) 
Then Kd = [(KT – (KN))(NT  –  (NK)]/[NK]      (4) 
Kd [NK] = NTKT– [NK](KT + NT) + [NK]
2 
[NK]
2 – [NK](Kd + KT + NT) + KTNT  =   0       ( 5 )  
The remaining concentrations are calculated using: 
[N] = NT – [NK]    and     [K] = KT – [NK]    (6) 
         
The fluorescence signal (S) measure is: 
S = SK[K] + SN[N] + SNK[ N K ]          ( 7 )  
where SK, SN, and SNK are the specific fluorescence intensities of K, N and NK, 
respectively. 
The data were fitted to the above equation with the specific fluorescence intensities 
and Kd as variables. A standard non linear least squares fitting procedure written by 
Dr. Stephen Martin (N.I.M.R.) was used. 
 
1.2 Competition and displacement Assays 
The values for the competition and displacement assays where determined according 
to the alternative model: A mixture of two competing nucleotide ligands,   146
mantATP/AMP or NADPH (N) and ATP/AMP (A), is titrated with the protein 
AMP-Kinase (K). If either Kd is known then the other can be determined. 
The AMP-Kinase (K) should interact with two ligands (N and A) according to the 
following scheme: 
K + N ↔ KN with KdB  =  ([K][N]/[KN]      (1) 
K + A ↔ KA with KdA  =  ([K][A]/[KA]      (2) 
Total concentration of protein, ligand M and A (KT, NT, and AT) are given by: 
KT  =  [K]  +  [KN]  +  [KA]        (3) 
NT  =   [ N ]   +   [ K N ]          ( 4 )  
AT  =   [ A ]   +   [ K A ]          ( 5 )  
Then  
[N] = KdN[KN]/[K] and NT = KdN[KN]/[K]  +  [KN]     (6) 
Then NT = [KN](KdN/ [ K ]   +   1 )       ( 7 )  
[KN] = NT/(KdN/[K] + 1) = NT[K]/(KdN  +  [K])     (8) 
In the same way one can show that 
[KA] = AT[K]/(KdA  +   [ K ] )         ( 9 )  
Substituting these expressions for [KN] and [KA] in the equation for KT gives: 
KT = [K] + BT[K]/(KdN + [K]) + AT[K]/(KdA  +  [K])     (10) 
Expanding this equation gives: 
[K]
3 + [K]
2(- KT + KdN + KdA + NT + AT) + [K](- KTKdN – KTKdA + KdNKdA + NTKdA 
+ ATKdN) – KTKdNKdA  =  0        (11) 
The remaining concentrations are calculated using 
[KN] = NT[K]/(KdN  +   [ K ] )         ( 1 2 )  
[KA] = AT[K]/(KdA  +   [ K ] )         ( 1 3 )  
[N] = KdN[ K N ] / [ K ]          ( 1 4 )  
[A] = KdA[ K A ] / [ K ]          ( 1 5 )  
The fluorescence intensity (S) is given by: 
S = SK[K] + SN[N] + SA[A] + SKN[KN] + SKA[KA]     (16) 
where SK, SN, SA, SKN and SKA are the specific fluorescence intensities of K, N, A, 
KN, and KA, respectively. The experimental data were fitted to the above equation   147
with the specific fluorescence intensities and the unknown association constant KdA 
as variables and KdN instead was held constant at the value measured with the direct 
fluorescence titration. A standard non linear least square procedure written by Dr 
Stephen Martin (N.I.M.R.) was used in the analysis. 
1.3 Fluorescent resonance energy transfer (FRET) 
Performing titrations in which the mant nucleotides are added to the AMPK (rather 
than adding the AMPK to the mant nucleotide) can, in principle give additional 
useful information. However, such experiments cannot easily be performed using 
direct excitation of the mant fluorophore because the change in fluorescence 
associated with the binding event(s) will be small compared with the fluorescence 
coming from the high concentration of free nucleotide reached at the end of the 
titration. However, because the emission spectrum of tryptophan overlaps the 
excitation spectrum of mant nucleotides it is possible to make use of resonance 
energy transfer 
223-224 by exciting AMPKs tryptophans at 290nm and monitoring the 
mant emission that derives from the energy transfer. Because the excitation of the 
free nucleotide is almost zero at 290 nm, the contribution from binding event(s) then 
becomes large relative to the contribution from the free nucleotide. 
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Appendix 2: Analysis of thermal shift data  
2.1 Basic theory for two-state transitions 
Despite the irreversible nature of protein unfolding for many large proteins at high 
protein concentrations, it has been suggested that irreversible unfolding may be 
treated as two discrete steps where a relatively fast folded to unfolded reaction is 
uncoupled from a much slower aggregation step 
226. Under this condition, an 
apparently irreversible process may be treated as a reversible unfolding transition. 
Protein unfolding is therefore described by the following: 
 
Consider the following simple two-state equilibrium between the folded (F) and 
unfolded (U) forms of a protein: 
FU
ku
kf
FU
ku
kf  
The unfolding constant is defined as:  
    ( 1 )  
Ku is related to the Gibbs free energy change (ΔG) by the following equations: 
RTLnK G − = Δ         ( 2 )  
where T is the absolute temperature and R is the Universal Gas Constant (0.0019872 
kcal/mol). 
the Gibbs-Helmholtz equation states: 
S T H G Δ − Δ = Δ          ( 3 )  
Where ∆H and ∆S are, respectively, the enthalpy and entropy of binding. For 
proteins, ΔH and ΔS are known to vary with temperature according to the following 
equations: 
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R − Δ + Δ = Δ         ( 4 )  
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where TR is any convenient reference temperature and ΔCP is the heat capacity 
change. 
Substituting equations (4) and (5) in equation (3) gives 
and  ()
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⎬
⎫
⎩
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TLn T T C S T H G
R R   ( 6 )  
This is known as the modified Gibbs-Helmholtz equation. 
 
The equation can be simplified further by letting the reference temperature be the 
midpoint of the unfolding transition (i.e., where the protein is, by definition, 50% 
unfolded and Fu = Ff = 0.5). By convention, the midpoint of the unfolding transition 
is designated as Tm. By definition: 
0 LnK RT G
m m T m T = − = Δ  
m
T
T T
H
S
m
m
Δ
= Δ           ( 7 )  
Substituting equation (7) in equation (6) and substitution of Tm for TR in equation (3) 
gives: 
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The optical signal at a given temperature in a thermal denaturation experiment can 
be related to the fractions of folded and unfolded protein present by: 
f u
f OBS
u S S
S S
F
−
−
=         ( 9 )  
Substituting in equation (1), gives: 
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Knowing that the optical signals characteristic of the folded and unfolded states (Sf 
and Su respectively) depended linearly on temperature according to: 
C f ) 0 ( f f T S S β + =          ( 1 1 )  
C u ) 0 ( u u T S S β + =          ( 1 2 )    150
And by substituting for ∆G  from  equation  (8)      
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          ( 1 3 )  
Where Sf(0) and Su(0) are the optical signals of the folded and unfolded states at 0
oC, 
TC is the temperature in 
oC, and ∆f and ∆u are the coefficients describing the linear 
temperature dependence of Sf and Su respectively. 
 
Data for the variation of SOBS with temperature can then be analyzed using non-
linear least-squares methods to give the thermodynamic parameters ∆H, Tm, and 
∆Cp, plus Sf and Su. In practice, ∆Cp is frequently set to a constant (or, more often, 
zero) because it is generally a small contribution to the unfolding and because it 
enables difficult transition curves to be solved more readily. 
 
2.2 Temperature dependence of association and dissociation constants 
Consider a protein (P) that binds a ligand (L) to form a simple 1:1 complex (PL) 
according to the following scheme: 
  
] ][ [
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L F
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Ka =    (14)     and     
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F
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Ku =    (1)  
where Ka is the association constant 
The unfolding constant in the presence of ligand, defined as Ku,APP, is given by: 
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At the midpoint of the thermal unfolding transition observed in the presence of the 
ligand, Tm(L), the concentrations of folded and unfolded forms must, by definition, be 
the same and one has from equation (15): 
] L [ K 1
K
1 K
) L ( Tm , a
) L ( Tm , u
APP , u +
= =         ( 1 6 )  
Where Ku,Tm(L) is the unfolding constant at Tm(L) and Ka,Tm(L) is the association 
constant for the binding of the ligand to the folded protein at Tm(L). The relationship 
between ligand binding and total free ligand, [LTm], at the Tm point is 
] L [
1 K
K
) L ( Tm , u
) L ( Tm , a
−
=        ( 1 7 )  
Therefore the association constant Ka,Tm(L) can be calculated when Ku,Tm(L)  is 
known. Analysis of the unfolding curve recorded in the absence of the ligand using 
equation (13) should yield ∆HTm , Tm, and (perhaps) ∆Cp. Note: Tm is the mid-point 
for unfolding observed in the absence of ligand. 
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and substitution of this value in equation (17) gives Ka,Tm(L). 
 
If one has estimates for both the enthalpy of binding, ∆HL, and binding heat 
capacity, ∆CpL, then the association constant, Ka, can therefore be calculated at any 
temperature from: 
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